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Electrical stimulation has been successful in treating patients who suffer from neurologic 
and neuropsychiatric disorders that are resistant to standard treatments. For deep brain 
stimulation (DBS), its official approved use has been limited to mainly motor disorders, 
such as Parkinson’s disease and essential tremor. Alcohol use disorder, and addictive 
disorders in general, is a prevalent condition that is difficult to treat long-term. To 
determine whether DBS can reduce alcohol drinking in animals, voluntary alcohol 
consumption of alcohol-preferring rats before, during, and after stimulation of the 
nucleus accumbens shell were compared. Intake levels in the low stimulus intensity 
group (n=3, 100μA current) decreased by as much as 43% during stimulation, but the 
effect did not persist. In the high stimulus intensity group (n=4, 200μA current), alcohol 
intake decreased as much as 59%, and the effect was sustained. These results demonstrate 
the potent, reversible effects of DBS. 
 
Left vagus nerve stimulation (VNS) is approved for treating epilepsy and depression. 
However, the standard method of determining stimulus parameters is imprecise, and the 





waveforms and assessing the nerve response to optimize stimulation selectivity and 
efficiency. VNS experiments were performed in rats aiming to increase the selectivity of 
slow nerve fibers while assessing activation efficiency. When producing 50% of maximal 
activation of slow fibers, customized stimuli were able to activate as low as 12.8% of fast 
fibers, while the lowest for standard rectangular waveforms was 35.0% (n=4-6 animals). 
However, the stimulus with the highest selectivity requires 19.6nC of charge per stimulus 
phase, while the rectangular stimulus required only 13.2nC.  
 
Right VNS is currently under clinical investigation for preventing sudden unexpected 
death in epilepsy and for treating heart failure. Activation of the right vagal 
parasympathetic fibers led to waveform-independent reductions in heart rate, ejection 
ratio, and stroke volume. Customized stimulus design with response feedback produces 
reproducible and predictable patterns of nerve activation and physiological effects, which 






CHAPTER 1. INTRODUCTION TO ELECTRICAL STIMULATION 
1.1 Medical Uses of Electrical Stimulation 
Many neurologic and neuropsychiatric disorders have no cure. Even for disorders 
that have established behavioral and pharmacological treatments, a significant amount of 
patients respond poorly and inconsistently. Parkinson’s disease1–3, epilepsy4,5, 
neuropathic pain6,7, alcoholism8–10, and depression11,12 are a few examples. Some 
conditions, such as neurological blindness and deafness, have no pharmacological 
treatments. These disorders and disabilities can be debilitating and pose high burdens on 
healthcare and society13,14. 
Electrical stimulation offers a safe and effective treatment for these conditions. 
Neuroprosthetics, with cochlear implants, vagal nerve stimulators (VNS), and deep brain 
stimulators (DBS) being the prominent examples, are now well known and common 
treatment options. Cochlear implants have been very successful in restoring hearing. 
However, because cochlear stimulation tends to be in a field by itself, it will not be 
discussed in detail. VNS has been FDA-approved for use in epilepsy and depression15, 
and DBS has been approved for treating Parkinson’s disease, essential tremor, and 
dystonia16. In addition, there are strong indications for other applications of VNS and 






To deliver effective treatments, the electrical stimulus must be both 
therapeutically efficacious and safe. For both VNS and DBS, overall efficacy has been 
solidly established, but patient response is highly variable. Also, modern stimulators are 
still plagued by side effects and complications, which are largely due to lack of 
selectivity and somewhat due to limited battery life, respectively16–19. Side effects differ 
among patients as well and can limit efficacy. Therefore, increasing the selectivity of 
stimulation and prolonging battery life can increase the effectiveness of treatment.  
As our understanding of the field improves, and as efforts continue to solve the 
major challenges, the technology has been evolving steadily, and the scope is becoming 
increasingly vast. The major aims of my thesis work were 1) to explore new areas to 
apply electrical stimulation and 2) to improve the current stimulation paradigm by 
introducing a new method of designing stimulus waveforms and analyzing the effects. In 
this first chapter, I review the key advances in the field of electrical stimulation and 
describe the current paradigm. This introduction chapter establishes the foundation and 
rationale for the experiments that follow.  
 
1.2 Historical Advances in Stimulation Paradigms 
To improve electrical stimulation therapy, refining stimulus design is the key. 
With more than two centuries of laboratory research and clinical studies, there exists 
abundant knowledge regarding how neural tissue responds to different stimuli.  
Guillaume Duchenne, in his book A Treatise on Localized Electrization20, 
attributed the first documented therapeutic uses of electricity to Kruger d'Helmstadt in 





electricity at the time, and involved devices such as Leyden jars, which stored and 
discharged static charge. This method is poorly controlled, has questionable efficacy, and 
can be dangerous. Fortunately, over time, both technique and understanding of electrical 
stimulation improved dramatically. 
First came direct current (DC) stimuli, mostly resulting from the Galvani-Volta 
debates at the end of the 18th century20–22. Then in early 1800’s, due to the birth of 
electromagnetism, alternating currents (AC) became available. The constant push and 
pull of electrical charge made it superior to DC stimuli20, but the push-pull also led to a 
lack of charge buildup in tissue, and efficacy is still low23. Indeed, even among modern 
waveforms, the biphasic charge-balanced pulse without delay, which resembles an AC 
waveform, is comparatively not so efficacious24–26. 
Batteries (voltaic cells) alone can only produce DC stimuli, but with a switch for 
completing and breaking the circuit, experimenters were able to produce interrupted DC 
waveforms. Using such waveforms, Emil du Bois-Reymond found that the response is 
much higher than DC and AC waveforms22. Circa 1850, he established the “general law 
of excitation of nerves”, which states that nerve activation is due to changes in current 
amplitude and not the exact amplitude22. 
At about the same time, Eduard Pflüger introduced his “law of contraction”27. In 
addition to supporting du Bois-Reymond’s law of excitation, Pflüger’s experiments also 
resulted in two important findings. The first is that excitation originates at the cathode, 
not the anode, upon making the circuit (this point will be discussed further in Subsection 





the anode. This “anode break excitation” has since been well-characterized28,29 and is 
regarded as an unintended effect that is to be avoided30,31,32. 
At the start of the 20th century, the monumental works of Georges Weiss and 
Louis Lapicque formed the foundation of modern electrical stimulation (their findings are 
discussed in Subsection 1.3.2)23,33–35. Their experiments contributed to a new paradigm 
that is still the standard today—pulsatile stimulation, where waveforms are constructed 
using brief pulses with defined parameters, such as pulse width and amplitude. Compared 
to interrupted DC waveforms, pulse waveforms have a much lower duty cycle but are 
still effective at activating excitable tissue. 
As a safer variant of simple pulsatile waveforms (monophasic), John Lilly and 
colleagues presented the biphasic pulse waveform (sometimes referred to as the Lilly 
waveform)36. Termed “zero net flow” by Lilly, these biphasic waveforms are now widely 
used, though monophasic pulses are commonly used as well. A comparison is provided in 
Subsection 1.3.6. 
After Lilly’s modification, there have been no major advances in stimulation 
paradigms. Not much has changed since the time of Weiss and Lapicque, over a century 
ago. However, the collective understanding of the mechanisms of electrical stimulation 
and the relationships between the stimulus and physiological response has increased 
substantially. The next section will synthesize key early discoveries reviewed above and 
some of the major concepts established more recently. These principles are important for 






1.3 Core Principles of Electrical Stimulation 
 
1.3.1 The Electrode-Tissue Interface 
Electrical stimulation acts by driving currents through tissue, which includes 
neurons, glia, and extracellular matrix. Delivering current into target tissue requires the 
use of electrodes. The study of electrodes is a vast field in itself, so only basic principles 
relevant to stimulus design will be discussed here. A thorough analysis of the 
electrochemistry of electrodes can be found in the well-known book by Bard and 
Faulkner37. An article by Stuart Cogan38 also offers a good review of electrode properties 
and design. 
Many electrode designs and configurations exist, including monopolar, bipolar, 
cuff, concentric, tripolar, etc. For simplicity, the analysis here will focus on the 
monopolar configuration, in which a single electrode serves as the working electrode 
while a second electrode serves as both the counter and reference. In this case, if this 
second electrode is implanted in distant tissue that is not of interest, its effects can 
essentially be ignored. 
When a voltage is applied across the working and counter electrodes, it drives a 
current between the electrodes and through tissue. With an ideal non-polarizable 
electrode, the stimulus current readily drives faradaic reactions at the electrode-tissue 
interface—electrons will be transferred across the interface via oxidation-reduction32,37,38. 
Significant faradaic reactions can damage both electrode and tissue. 
In contrast, with an ideal polarizable electrode, electrons cannot cross the 





is termed the “double layer” at the interface, which behaves like a capacitor37. A more 
detailed description of the double layer can be found in Chapters 1, 10, and 13 of the 
Bard-Faulkner book37. 
The electrochemical behavior of the stimulating electrode, target tissue, and the 
interface can be approximated as an electrical equivalent circuit. While many circuit 
models exist, this document will focus on the famous Randles model39, shown in Figure 
1. This model also applies to the counter and reference electrodes. 
Re is the resistance of the electrode material; the impedance due to Re tends to be 
negligible relative to that of other components. Zm denotes the passive impedance of the 
medium, which is a conductive solution or tissue. In a solution, Zm is purely resistive, 
but in tissue, Zm is complex. The Rf and Cf terms represent, respectively, the resistive 
and capacitive behavior of faradaic charge transfer at the interface. These two terms 
collectively form the faradaic impedance, Zf. Cdl represents the double layer capacitance.  
Each component of this circuit model is associated with a physical phenomenon 
and can be used to infer characteristics of the electrode and tissue. Zf and Cdl are 
particularly important. For example, a highly polarizable electrode with high Zf and large 
Cdl is great for stimulation. The significance of a large Cdl is that, given a voltage, more 
 
Figure 1 The Randles equivalent circuit model for the electrode-tissue interface. 
Please see text for description and explanation. The figure is created based on 





charge can be injected into the double layer. A high Zf allows the electrode to sustain 
higher voltages without undergoing significant faradaic reaction. Zm is also important. 
For chronic implants, Zm typically increases over time, which is attributed to tissue 
encapsulation. Tissue encapsulation is an innate response and adversely affects 
treatment40–43. 
To determine these circuit components for a particular system, electrochemical 
impedance spectroscopy (EIS) is commonly performed38,41,44,45. EIS builds the voltage-
current relationship of the system by measuring the impedance to sinusoidal voltage 
signals over a large range of frequencies. The impedance data then can be used to 
construct a circuit model with quantified component values. EIS theory is discussed in 
detail in Chapter 10 of the Bard-Faulkner book37 and by Andrzej Lasia46. 
The properties of the electrode-tissue interface create major limits for stimulus 
design and the device. For example, smaller stimulating electrodes can be more region-
specific but have smaller Cdl. A small Cdl results in higher impedance, which increases 
the stimulator voltage required to deliver the same therapeutic level of current and the 
overall power consumption. 
 
1.3.2 Strength-Duration Relationships 
Georges Weiss developed instruments to generate brief, voltage-controlled 
rectangular pulses, of which both the pulse width and voltage amplitude can be precisely 
adjusted. Using this pulsatile stimulation, he built a mathematical model that relates nerve 
responses to stimulus parameters. In 1901, he proposed the following formula: 





where “t” is the pulse width (duration) and “Q” the product of the threshold voltage 
amplitude for nerve activation and pulse width33,34. “a” and “b” are merely empirical 
constants used to fit the data to a linear regression model. Today, “Q” is defined as the 
product of threshold current and pulse width, which for rectangular pulses, is the charge 
injected by the pulse.  
In a follow-up article in 19091, Louis Lapicque expanded upon Weiss’s model 
and defined the terms “rheobase” (“rhéobase” in French) and “chronaxie”35. The 
rheobase is the theoretical minimum pulse voltage required to activate a nerve using an 
infinite pulse width. The chronaxie is the pulse width required to activate a nerve when 
using a pulse voltage twice the rheobase. Again, today, these concepts are described 
using current amplitudes. 
The relationships described by Weiss and Lapicque are now known as the 
strength-duration relationships (Figure 2). The strength-duration equations, written 
below, relate the threshold current (Ith), threshold charge (Qth), and threshold energy (Eth) 
required for nerve activation to pulse width (t), rheobase (Ir), and chronaxie (tc)34,47,48. 
For energy, a constant resistance (R) is assumed. 
 𝐼𝑡ℎ = 𝐼𝑟 (
𝑡𝑐
𝑡
+ 1)  Equation 2 
 𝑄𝑡ℎ = 𝐼𝑡ℎ ∗ 𝑡 = 𝐼𝑟 𝑡𝑐 + 𝐼𝑟 𝑡  Equation 3 
 𝐸𝑡ℎ = 𝐼𝑡ℎ
2 ∗ 𝑅 ∗ 𝑡 = 𝐼𝑟
2 𝑅 𝑡 (
𝑡𝑐
𝑡
+ 1)2  Equation 4 
                                                 
1 This article is actually located in Comptes Rendus Soc Bio. The article is sometimes wrongly cited as 
Comptes Rendus Acad. Sci. Lapicque did publish an article in the same year there, but it was not the one 





These equations do not perfectly fit empirical data but are close approximations; 
reported r2 is usually > 0.9948–50. It is important to note that, for pulse shapes other than 
rectangular, the current-duration relationship still holds true, but the average, not the peak, 
current should be used for analysis34. Also, it is interesting to note that, though Weiss and 
Lapicque used voltage-controlled stimuli in their experiments, they presented their 
models in terms of I and Q.  
The strength-duration equations and curves illustrate clearly the importance of 
pulse width in determining efficacy: 
1. The longer the pulse width is, the lower the threshold current is.  
2. The shorter the pulse width is, the less the threshold charge is.  
3. At the chronaxie, the lowest energy is needed.  
 
Figure 2 Strength-duration curves. The black dashed line illustrates Equation 2. 
The black dotted line illustrates Equation 3. The black solid line illustrates Equation 
4. The rheobase current is set to an arbitrary value of 1, and so is the chronaxie. All 
values on the axes are therefore relative to the rheobase (gray solid line) and chronaxie 






While strength-duration relationships were first created for studying nerve 
activation, these principles certainly can be applied to brain stimulation as well. Charles 
Gallistel and colleagues published a series of articles in the 1970s that characterized the 
relationship between stimulus pulse width and the charge required to elicit reward-
seeking behavior in rats51–53. Though the data tend to deviate more from the models, the 
general relationship does hold true. Other laboratory54,55 and clinical56,57 studies also 
agree with this finding. 
 
1.3.3 Current-Distance Relationship 
When driving currents using electrodes, a voltage profile that is dependent on 
tissue impedance develops in tissue (good illustrations of such voltage profiles can be 
found in 58–61). Therefore, a relationship exists between threshold current and distance of 
a neuron from the electrode, which takes on a parabolic shape, with threshold current 
increasing with increasing distance62. The existence of such a relationship is easy to 
appreciate, and the concept is rather intuitive. Thus, the details of the current-distance 
relationship will not be discussed further here. A 1996 article by Edward Tehovnik63 
offers a good review of this principle. 
This relationship is very important in brain stimulation, where, less so for nerves, 
tissue organization and function vary highly with respect to space. So, when stimulating a 
specific region, much of the neural tissue near the electrode will be activated, leading to 
the therapeutic effect. However, a portion of the tissue surrounding the target region will 
be activated as well, leading to side effects. Ensuring adequate stimulation of the target 






1.3.4 Electrical Properties of the Neuron 
Neurons respond to electrical stimuli by changing their membrane properties. 
Activating a neuron is simply inducing an action potential. The renowned Hodgkin-
Huxley study28 essentially created an equivalent circuit that describes the behavior of 
neuron membranes to an applied current (see Figure 3 for a simplified model).  
The mechanism of the action potential lies in 
the dynamics of the channel conductances. The 
membrane voltage is a function of the Nernst 
potentials and conductances of the many types of ion 
channels28,64. The Nernst potentials are fairly constant, 
but the conductance of each channel type varies 
differently with membrane voltage and time. If the 
resting membrane is depolarized past the threshold 
voltage, due to a natural or artificial stimulus, changes 
in conductances are initiated, resulting in the action 
potential28. 
Though the Hodgkin-Huxley model was built 
for the isolated axon, similar models can be built for 
the neurons of the central nervous system. These 
models can be used to study and predict how different 
axon fiber populations58,65–67 and different 
compartments of the neuron, such as dendrites and 
somata68–70, respond to electrical stimuli. 
 
Figure 3 Simplified 
Hodgkin-Huxley model. Vo 
and Vi denote the potentials 
on the outside and inside of 
the membrane, respectively. 
Cm models the membrane’s 
capacitive behavior. Em 
represents the membrane 
voltage, and gm is the 
membrane conductance 
lumped from all the channels 
(note g = 1/resistance). By 
modern convention, Em = 
Vi - Vo, and the current I is 
positive flowing from inside 
to outside. Modified from 






1.3.5 Cathodic versus Anodic Stimulation 
Based on the Hodgkin-Huxley model and its conventions, the membrane is 
negatively polarized at rest, meaning there is an excess of negative charge on the inside. 
If an outward current is induced, it will depolarize the membrane, and vice-versa28,71. To 
produce an outward current, the working electrode is driven to a negative potential, 
termed cathodic stimulation. Negative charge then accumulates near the extracellular side 
of the membrane, leading to depolarization, which subsequently can initiate an action 
potential. Note that in electrical stimulation, the intracellular compartment is not directly 
manipulated. 
On the other hand, when the working electrode is driven to a positive potential—
anodic stimulation—positively charged ions will accumulate, leading to 
hyperpolarization. However, anodic stimulation can still elicit action potentials in nerves 
or axons via the creation of what Merrill et al. referred to as a “virtual cathode”32, which 
is a relative cathodic field that surrounds the applied anodic field 58,71,72. These virtual 
cathodes are weaker in amplitude than a directly applied cathodic field, and so the 
expected efficacy is lower as well. 
Indeed, for neuronal activation, modeling58,65,66 and empirical evidence73,74 both 
suggest that cathodic pulses are more efficacious75. For DBS, results from laboratory54 
and clinical studies76 also support the use of cathodic pulses. 
For cortical stimulation, when using penetrating electrodes, like those used in 
DBS studies, cathodic stimulation is also more efficacious62,77,78. However, when using 
surface electrodes to stimulate the cortex, researchers have shown that anodic stimulation 






current-distance relationship, it is difficult to activate deeper axon-rich layers with 
cathodic pulses from the surface. In this case, to target the axon-rich layers, anodic 
stimulation can be used to create virtual cathodes deeper in the cortical tissue. 
 
1.3.6 Monophasic versus Biphasic Stimulation 
As mentioned earlier, biphasic waveforms are used mostly for safety reasons. By 
principle discussed previously, biphasic waveforms usually are cathode leading. The 
initial cathodic pulse is intended to depolarize the neurons, eliciting action potentials. The 
charge injected by the cathodic pulse is then reversed by the anodic pulse that follows, so 
that there is no potential buildup that could lead to faradaic reactions. Cathode leading 
has been shown to yield lower threshold currents in nerve stimulation25 and cortical 
stimulation78. 
Though there is disagreement81,82, overwhelming evidence suggests that biphasic 
stimuli are indeed safer15,80. The tradeoff, however, is that biphasic waveforms are less 
efficacious, with the delay between cathodic and anodic pulses being an important 
factor24–26. 
 
1.3.7 Current- versus Voltage-Controlled Stimulation 
Whereas all articles up to Weiss’s and Lapicque’s time described using voltage-
controlled stimuli, as early as Penfield’s homunculus experiments, experimenters began 
to report that current-controlled stimuli tend to be more consistent and effective85,86. 
Today, overall, current-control is the standard. In this paper, “current-control” refers to 






“voltage-control” refers to applying a defined voltage across the working and counter 
electrodes. 
The major disadvantage of using voltage-controlled stimuli is that only the 
voltage between the working and counter electrodes is controlled32. At the pulse onset, 
when the capacitive components of the electrode and tissue are not charged, the current is 
high, but as they charge, the current will decrease. In addition, because the electrode and 
tissue impedances are both variable over space and with time, the voltage profile through 
the tissue is inconsistent. 
Based on these observations, from an efficacy perspective, voltage-control offers 
poor reproducibility32. Indeed, modeling has shown that, with voltage-controlled stimuli, 
the volume of tissue activation and the voltage profile are highly dependent on electrode 
and tissue capacitances87. In a recent investigation, Lempka et al. have shown that 
voltage-controlled stimulation causes significantly larger variability in the voltage 
recorded from recording electrodes near the DBS electrode88. And from a safety 
perspective, though the voltage is set, electrode potentials can drift over time with 
repeated stimuli, especially with high frequency pulses, which leads to undesirable 
faradaic reactions32,81,82. 
Voltage-control is mainly seen in DBS, where the voltage amplitude requires 
constant readjustment89–92. Recently, this DBS paradigm has been called into question93. 
Laboratory experiments88,94 and randomized clinical trials95 have shown that current-








1.4 Modern Stimulation Paradigms 
The standard modern stimulus waveform is composed of a train of repeating pulse 
waveforms. Important parameters regarding each pulse are listed below: 
 Pulse shape – examples include rectangular, triangle, and sinusoid 
 Amplitude (AMP) – amplitude of the pulse, either voltage or current 
 Pulse width (PW) – the duration (a time value) of each pulse 
Though many pulse shapes have been proposed and studied96–99, the rectangle is 
still the most common shape used in research and clinical settings. Used since the time of 
Weiss and Lapicque, it is popular due to its ease in implementation and mathematical 
simplicity. 
A pulse train then can be formed using single pulses—monophasic—or biphasic 
pulse waveforms. Important biphasic pulse parameters are: 
 Cathodic amplitude – amplitude (either voltage or current) of the cathodic 
pulse 
 Anodic amplitude – amplitude of the anodic pulse 
 Interphase delay – the delay (a time value) between cathodic and anodic 
phases; this value could be 0 and usually is not longer than the interpulse interval  
 Interpulse interval – the time between the end of the first pulse and the 
beginning of the following pulse 
Biphasic waveforms can lead with either the cathodic or anodic phase. In addition, the 
pulse widths and amplitudes of each phase can be intentionally mismatched. And finally, 
the pulse train has the following important parameters: 






 Pulse repetition frequency – this is equal to 1/period and is commonly 
referred to as the stimulation frequency  
Figure 4 illustrates a pulse train, with parameters annotated, constructed from biphasic, 
charge balanced, pulse waveforms with interphase delay.  
In certain applications, more complex features are introduced into the stimulus 
waveform in the form of amplitude (AM) and/or frequency modulation (FM) of the 
parameters. In AM, the amplitude parameters of the individual pulses within the train are 
varied; in FM, the time parameters are varied. In auditory stimulation and cochlear 
implants, the advantages of AM and FM are well-established100,101. Similar work is being 
conducted for DBS102,103. 
 
1.5 Overview of Dissertation 
The contents of this introduction chapter so far have described the current state of 
the broad field of electrical stimulation. CHAPTER 1 only serves as a general review of 
the established theory and principles. The next three chapters all deal with specific 
 
Figure 4 Example pulse train. The waveform above is a biphasic, charge balanced, 






applications of electrical stimulation in medical science and practice. Each of these 
chapters contains a further review of relevant background information and key findings.  
CHAPTER 2 explores the effects of electrical stimulation on alcoholism, a 
condition that affects many and has proven to be difficult to treat with conventional 
methods. The neural circuitry of reward and addiction has been studied for many decades, 
and by stimulating the appropriate parts of that circuit, it is theoretically possible to 
modify addiction behavior. Others have attempted to reduce alcohol consumption in 
animal studies but have not produced convincing results104,105. Through collaboration 
with Dr. Zachary Rodd’s group in Indianapolis, I was able to show that DBS of the 
nucleus accumbens shell reduced alcohol drinking in rats. These results have important 
implications for treating alcoholism and addiction. 
CHAPTER 3 introduces a novel method of designing and studying stimulus 
waveforms that has potential to increase the effectiveness of stimulation therapy. This 
work originated from the DBS work described in CHAPTER 2. When applied to nerve 
stimulation, the vagus nerve in particular, this novel method seems capable of producing 
patterns of nerve fiber activation different from the conventional method, which simply 
involves delivering rectangular pulse waveforms. The different activation patterns signify 
that the efficiency and selectivity of nerve stimulation can be fine-tuned with careful 
adjustments of the stimulus based on response feedback. 
In CHAPTER 4, the work in CHAPTER 3 is expanded. In addition to 
demonstrating how the stimulus can be manipulated to vary the nerve activation pattern, I 
show that the differences in the resulting nerve response profiles have a significant 






consistent relationship with the ultimate physiological response. As a result, a stimulation 
paradigm that allows improved control of the nerve response also provides better control 
of the physiological response. 
CHAPTER 5 concludes all of the work detailed in this dissertation. This final 
chapter reviews the key concepts and summarizes the important results. And finally, there 







CHAPTER 2. DBS TO TREAT ALCOHOL USE DISORDER 
2.1 Introduction to Alcohol Use Disorder 
Alcohol use disorder (AUD) – alcohol abuse and dependence – is a highly 
prevalent condition with serious health and societal impacts14,106,107. An estimated 30% of 
the U.S. population will suffer from AUD during their lifetime106, and in the world, about 
125 million people suffer from AUD14. Patients with AUD have 1.8 to 9.5 times higher 
mortality rates than the general population, and death from accidents, particularly motor 
vehicle collisions, is common108–110. Existing treatments can be effective but only 
temporarily so, because about 50% of patients become noncompliant or relapse in just 
one month8,9,111–113.  
Deep brain stimulation (DBS) offers a promising alternative to conventional AUD 
treatments16 and may provide reliable treatment with sustained long-term effectiveness. 
Recent clinical studies and reports have shown that DBS can reduce alcohol intake and 
craving114–116 as well as other addictive behavior, such as cigarette smoking, drug use, 
and overeating117–119. Animal studies suggest the same104,105,120–123. However, there are 
still concerns about beginning large-scale clinical trials. The major criticism is that there 
is not enough evidence on long-term efficacy and safety in animals to justify such an 






There is actually not much animal data on the effects of DBS on alcohol 
consumption in general124–127. One study showed that DBS can reduce alcohol intake but 
relied on a saccharin fading procedure to induce alcohol drinking105. Another study used 
P-rats, which voluntarily drink alcohol, but the study yielded inconclusive results due to 
very low levels of alcohol intake104. The P rats are a unique breed of rats with 
characteristic alcohol preference and intense alcohol drinking behavior128,129, which make 
them a good model for studying alcoholism130,129. 
This chapter presents a set of experiments characterizing the effects of DBS on 
voluntary ethanol consumption in the P rats. These experiments were aimed to provide 
more efficacy data from animal studies. The results of this work contributed to the 
increasing amount of evidence that supports the use of electrical stimulation in treating 
AUD and related disorders. 
 
2.2 Experimental Design and Methods 
These experiments were designed and conducted in collaboration with Dr. 
Zachary Rodd’s research group in Indianapolis. The animal experimentation took place in 
Indianapolis. 
 
2.2.1 Animals and Surgery 
Adult female alcohol-preferring (P) rats weighing 200 to 350 gm from the 78th 
generation were used in this experiment. Female rats were used because they maintain 
body weight and head size better than male rats for more accurate stereotactic placements. 






dark cycle (lights off at 9:00 AM). Food and water were freely available throughout the 
experiment except in the test cage. Animals used in this study were maintained in 
facilities fully accredited by the Association for the Assessment and Accreditation of 
Laboratory Animal Care. All research protocols were approved by the institutional 
animal care and use committee and are in accordance with the guidelines of the 
Institutional Care and Use Committee of the National Institute on Drug Abuse, NIH, and 
the Guide for the Care and Use of Laboratory Animals (National Research Council, 
1996). 
A twisted pair of Platinum electrodes (Plastics One, Inc.) was implanted into the 
left nucleus accumbens shell (AcbSh) of each animal. The AcbSh is a major center in the 
reward/addiction circuitry131,132. Unilateral implantation was performed instead of 
bilateral, mainly to simplify the surgery and experimentation. Left sided implantation was 
chosen based on a previous human study, which demonstrated abnormal neural activity in 
the left AcbSh only (i.e. no change in right AcbSh) in response to drug-related cues115. 
Target coordinates for the AcbSh were 1.6 mm anterior to bregma, 2.4 mm lateral to the 
midline, and 8.5 mm ventral from the surface of the skull at a 10-degree angle to the 
vertical.  
Each electrode terminated in two female sockets that were connected to a multi-
channel electrode pedestal, which was secured firmly using cranioplasty (OrthoJet) 
layered around the device and over three stainless steel screws fastened to the skull. After 








2.2.2 Experimental Setup 
The DBS system consisted of an “animal proof” stainless-steel-shielded cable that 
attached the implanted electrode pedestal and to an electrical commutator (all from 
Plastics One, Inc.), which allowed free movement within the cage. The commutator was 
mounted over the top of the testing cage, which is 30 x 30 x 26 cm (w x h x d) in size. A 
waveform generator (Agilent 33522A) was used to design the stimulus waveform, and a 
custom-made current pump was used to convert the voltage waveform to a constant 
current waveform (more detail on the current pump can be found in Section 3.6). The 
stimulus parameters were as follows: biphasic, rectangular pulses with no interphasic 
delay, pulse frequency 150 Hz, pulse width 100 μsec, and current intensities of 100 μA 
(n=3) or 200 μA (n= 4). 
The implanted electrodes were checked periodically by performing 
electrochemical impedance spectroscopy with a Gamry Reference 600 Potentiostat 
(detailed methods can be found in Section 3.6). The functionality of the DBS system was 
tested before each stimulation session by checking the stimulator output via a digital 
multimeter (Agilent 34410A) in series with the stimulator and electrodes. All 
measurements were done outside the 60-min testing session and did not interfere with 
behavior testing. 
 
2.2.3 Experimental Design and Data Analysis 
In the testing cage, 15% non-flavored ethanol (EtOH) and water were freely 
available, via two separate 15 mL graduated tubes. Rats were placed in the training box 






establish consistent alcohol intake behavior. Alcohol-preferring P rats are natural drinkers 
and do not typically require food/water restrictions, or sucrose fading procedures to 
acquire stable daily alcohol intake in a free choice limited access setting128,129. Once 
chronic drinking levels were established and stable over several days, rats underwent 
surgery for DBS lead placement. After a recovery period of 2 days, the rats resumed the 
daily 1-hour sessions in the training box. 
During the first postoperative week, the rats were tethered to the DBS system but 
did not receive any active stimulation. This period allowed each rat to acclimate to the 
new sensation of the cable and reach a new post-implant baseline of alcohol intake. In the 
second postoperative week, once rats re-established alcohol drinking behavior, DBS was 
delivered to the rats in the training box for 5 minutes prior to and during the entire 60 
minute drinking session.  
DBS therapy occurred each day during the 1-hour session for 5 days at 100 μA in 
3 rats and for 6 days at 200 μA in 4 rats. A technical issue in the 100-μA group caused 
the DBS to not be delivered on Day 1, but this was not identified until after the 
completion of the experiment, leaving just five days of active DBS data for analysis. All 
7 rats underwent an additional 3 daily post-DBS sessions, during which they were 
tethered but not stimulated to assess for any post-treatment effects. At the completion of 
the experiment, rats were euthanized by CO2 inhalation. Brains were then removed, and 
histology was examined for accurate placement of electrodes to confirm proper 
implantation. 
The analysis for the DBS data was simplified since there were not enough values 






Therefore, paired t-tests were performed comparing baseline EtOH consumption to intake 
during test session. To adjust for multiple comparisons, the p value of significance was 
lowered to p < 0.01. 
 
2.3 The Effect of DBS on Alcohol Intake 
DBS delivered at 100 μA temporarily reduced EtOH consumption (see Figure 5) 
with 35% and 43% decreases on Days 2 and 3 (p values < 0.002) but no effect on Days 1, 
4, and 5. DBS delivered at 200 μA consistently reduced EtOH consumption, with a 35%, 
42%, 53%, and 59% decrease on Days 3, 4, 5, and 6, respectively (p values < 0.0018; 
Figure 6). There was no effect of DBS on water intake, indicating that the stimulation 
did not affect overall fluid intake or interfere with normal animal behavior. Baseline 
intake levels in both groups would have resulted in blood ethanol concentrations ranging 
from 75-125 mg%; these levels are much higher than what others reported104. 
 
Figure 5 Ethanol (EtOH) intake in the 100μA group. The average EtOH intake per 
1-hour session is plotted over time. Data were collected each day during DBS delivery 
Stim1–Stim5) and for 4 days after the last day of DBS delivery (Post1–Post4). 
Baseline is estimated by averaging the intake for 3 days before stimulation. Data were 






At 100 μA, there seems to be only a transient decrease in alcohol intake in the 
subjects. However, at 200 μA, the effect is more sustained. Also, the effect seems to be 
reversible, with intake rebounding to baseline levels after the stimulation either is no 
longer effective or is turned off.  
 
2.4 Discussion 
DBS of the AcbSh seemed to be capable of reducing alcohol drinking in alcohol 
preferring P rats. Considering that the overall amount of stimulation is fairly low, only 
about 1 hr per day, and that only unilateral stimulation was delivered, the observed 
significant effect on alcohol drinking behavior is highly promising. DBS may just 
provide the type of lasting treatment that is specific, adjustable, and less dependent on 
patient compliance. 
 
Figure 6 Ethanol (EtOH) intake in the 200μA group. The average EtOH intake per 
1-hour session is plotted over time. Data were collected each day during DBS delivery 
(Stim1–Stim6) and for 3 days after the last day of DBS delivery (Post1–Post3). 
Baseline is estimated by averaging the intake for 3 days before stimulation. Data were 






However, as can be seen in the difference between the 100 and 200 μA test 
groups, the stimulus parameters can dictate the success of the therapy. The two 
amplitudes, 100 and 200 μA, were chosen somewhat arbitrarily when designing the 
experiment, with prior studies in mind104,105. Though the final behavioral effect can be 
measured, the exact neural response to the stimulation is unknown.  
With only physiological or behavioral data as feedback and no neural response 
data, it is difficult to determine the stimulus parameters to ensure that the patient or 
subject is receiving appropriate stimulation. Too little stimulation can result in lack of 
therapy or loss of therapy over time, as seen in the 100 μA group. Too much stimulation 
may result in harmful side effects. Dosing for each individual is a major challenge in the 
field of electrical stimulation today. 
 
2.5 Developing a Better Method for Stimulus Waveform Design 
The next two chapters present a new way to design and assess stimulus 
waveforms. The work builds on the thesis of Dr. Matthew Ward133, who provided a 
stimulation system to characterize and analyze the neural responses to different stimuli. 
This system, termed Autonomous Neural Control (ANC), allows users to empirically 
determine how neurons will respond to stimulation. The neural response then can be 
matched to the physiological or behavioral response. This way, determining the stimulus 
parameters can be objective, involving less guesswork. 
So far, ANC is best developed for nerve stimulation, with particular focus on the 
vagus nerve due to the many applications of vagus nerve stimulation therapy. When 






organized, essentially parallel bundle of axons, whereas the brain is a vast network. 
Though the nerve response can be more easily captured and quantified, the vagus nerve is 
by no means simple. Stimulating the vagus nerve can cause many different effects, and 
these effects can be matched to the nerve response. Therefore, vagus nerve stimulation 
provides a good platform for testing methods to optimize stimulus parameters. 
 
2.6 Notes 
With permission from Journal of Neurosurgery, some portions of the texts and 
several figures in this chapter were reproduced and adapted from the published article 
Wilden et. al.134, which is the fruit of the collaboration with Dr. Rodd’s group and 







CHAPTER 3. BURST-MODULATED STIMULUS WAVEFORMS 
3.1 Introduction to Vagus Nerve Stimulation and Its Challenges 
Electrical stimulation of the vagus nerve is an FDA-approved treatment for 
certain types of epilepsy that are resistant to conventional treatments. Vagus nerve 
stimulation (VNS) is also approved for treatment-resistant major depression, and it is 
under investigation for treating other disorders15. In epilepsy, up to 24% of patients 
cannot adequately control their seizures with medication4,5, and among patients being 
treated for depression, as many as 50% experience recurrent major depressive episodes135. 
Some of these patients, who do not respond to pharmaceutical therapy, do respond 
positively to VNS. Response rate to VNS is about 25-45% in patients with drug-resistant 
epilepsy17 and about 30-40% in patients with drug-resistant depression136. Though the 
anti-depression effect is highly significant, the contents of this chapter will focus mostly 
on VNS in epilepsy, the major reasons being that VNS in epilepsy has been studied in 
more detail and that the effects are more quantifiable. 
A significant amount of patients benefit from VNS, but there are many patients 
who do not respond well. Clinical studies generally conclude that patient response rates 
increase with time, and tolerability to the stimulation increases as well137–140. However, a 
closer look at the clinical VNS data will show that, patients who initially responded to 






unresponsive. Ultimately, the patients who do not respond tend to stop treatment. For 
example, in a key clinical trial by DeGiorgio et. al.137, 164 patients completed the study, 
and out of those, 68 patients were responders, with “response” defined as 50% reduction 
in the number seizures. Of the 98 remaining patients, 22 discontinued therapy, and the 
mean seizure reduction in this group is only 7%. A retrospective study by Labar138 found 
that patients receiving higher levels of stimulation are actually less responsive, and that 
patients with more severe epilepsy tend to be less responsive.  
Currently, the method for determining VNS parameters—the method of dosing—
is not an exact process. Patients pay multiple clinical visits and have their care providers 
manually adjust the stimulation parameters. The intensity is increased slowly and set to a 
point slightly lower than the maximum level that the patient can tolerate. If symptom 
relief is not enough, then the physician will attempt to increase the stimulation level 
without exceeding the maximal tolerable level141. Adjustment is mostly based on the 
patient’s perception and the physician’s intuition (there is a safety limit as well that is 
somewhat arbitrary). It is not surprising, then, that patients who do not respond well to 
VNS are the ones to receive higher and higher levels of stimulation, and that if a patient 
does not respond initially, it will be difficult to improve the effects in that patient. 
Increasing the overall response rate and reducing the variability among patients 
are major challenges. After reviewing the background of VNS, this chapter will propose a 
strategy aiming to improve the effectiveness of VNS. This strategy is based on existing 
knowledge in the field as well as data collected through original experiments, and it is 







3.2 Mechanism of Electrical Nerve Stimulation 
In VNS, electrical charge is applied to the nerve to depolarize the axons within 
the vagus nerve, evoking action potentials. Generally, electrical charge is delivered 
through a set of cuff electrodes that wrap around the nerve. The charge is supplied by a 
stimulus generator, which is powered by a battery. The electrodes, stimulator, and battery 
are all implanted inside the body (see Figure 7). When a stimulus is applied across the 
electrodes that are placed near the nerve, charges move and distribute in the space 
surrounding the electrodes and the nerve. In this type of extracellular stimulation (as 
opposed to intracellular stimulation techniques that require accessing the intracellular 
space), axons will generate action potentials if their membranes are depolarized 
sufficiently by the movement of charges.  
 
Figure 7 The Cyberonics VNS device. Left) An illustration of the VNS implant, 
composed of the electrode cuffs, connecting leads, and the stimulus generator housed 







Though it affects all axons within the nerve, the stimulus has a stronger effect on 
the axons nearer to the nerve periphery and closer to the electrodes. However, since there 
is not enough evidence to suggest that the axons within the vagus nerve are spatially 
distributed in a consistent, predictable manner, VNS is not specific for axons with respect 
to the axon’s target and function. 
Aside from target and function, there are factors that do influence how individual 
axons respond. In the vagus nerve, as in the entire peripheral nervous system, some axons 
are myelinated by Schwann cells. The axon together with its myelin sheath, Schwann 
cells, and endoneurium are referred to as a nerve fiber; the term fiber pertains to even the 
unmyelinated axon with its endoneurium. In the vagus nerve, 70-90% of all nerve fibers 
are unmyelinated, and the rest are myelinated to different degrees142,143. The axons with 
larger diameters tend to have more myelination144, and the larger, more myelinated fibers 
conduct action potentials at faster velocities145–147. Nerve fibers are historically grouped 
by their conduction velocities as summarized in Table 1 (compiled from multiple 
sources15,142,146,148,149).  
With typical electrical stimuli, fast-conducting fibers have lower activation 
thresholds24,58,97,150–152—the lowest stimulus intensity that can elicit an action potential. 
The smaller, slow-conducting fibers of the nerve are harder to activate50,153,154. Therefore, 
though all the axons are affected during stimulation, generally more of the larger, faster 
fibers will respond to each stimulus. As such, electrical stimulation is intrinsically 








Table 1. Nerve fiber classification and function 
 A fibers B fibers C fibers 
Diameter (micron) 
 
5 – 10  2 – 5  < 2 
Myelination 
 
Thick Thin None 
Conduction 
velocity (m/s) * 
> 10 1.5-20 < 6 
Direction 
 
Efferent & afferent Efferent Afferent 











Low Medium High 
* Large overlap in conduction velocity range is due to discrepancies, which may arise 
from differences in recording setups, animal models, and methods of calculation. 
 
3.3 Effects of VNS 
The vagus nerve (cranial nerve X) is a large collection of axons that innervates 
tissues and organs spanning from the face/head region down to the colon. The axons that 
innervate skeletal muscles for swallowing and speech originate from the nucleus 
ambiguus in the medulla. The soma in the nucleus ambiguus also send efferents to the 
heart, which, together with the efferents to the respiratory and abdominal organs from the 
dorsal motor nucleus (also in medulla) of the vagus, constitute the major parasympathetic 
pathway of the body. In addition to efferents, the vagus nerve contains many sensory 






nerve relays general sensation to the spinal trigeminal nucleus. More importantly, vagal 
afferents are responsible for monitoring the cardiovascular and respiratory systems, 
digestive, and other abdominal organs. These pseudounipolar axons synapse in the 
nucleus tractus solitarius (NTS)155. Figure 8 illustrates key components of the functional 
anatomy of the vagus nerve.  
 
Figure 8 The vagus nerve anatomy and composition. Only the proximal portion, 
down to the thoracic region, of the vagus nerve is shown. Nearby nerves are illustrated 






Due to the complex nature of the vagus nerve and the nonspecific nature of 
electrical stimuli, VNS can create a wide range of effects in the body, some of which are 
on the heart and are of particular importance. Stimulating cardiac portions of the vagus 
nerve on either the left or the right side will activate the parasympathetic efferents to the 
heart, producing negative chronotropic (decreased heart rate), inotropic (decreased 
contractile force), and dromotropic (decreased conduction) effects. The left and right 
vagus nerves both innervate the heart, but they are not symmetric156. Stimulating the right 
vagus has strong negative effects on heart rate and contractile force, and though 
stimulating the left vagus has stronger negative effects on the atrioventricular nodal 
conduction156–158, this dromotropic effect is less of a clinical concern than the bradycardia 
and low cardiac output caused by stimulating the right vagus. Therefore, in patients with 
epilepsy, VNS implants are typically only implanted on the left side, so that harmful 
cardiac effects are avoided. 
Heart-related effects aside, the other effects of VNS can also have clinical impact 
on patients; these effects are mostly side effects. Ignoring the surgery- and device-related 
complications (such as infection, scarring, etc.), side effects manifest in the nervous 
system (pain, paresthesia, headache, dizziness, etc.), respiratory system (dyspnea, 
pharyngitis), and in the digestive system (dysphagia, nausea, vomiting). The most 
common ones are coughing and hoarseness/voice alterations136,140,141,159,160, which 
correspond to the stimulation of the motor efferents to the larynx. Since the motor 
efferents, which are the fast conducting fibers, generally are the easiest to activate, it is 
not surprising that VNS leads to strong motor-related side effects. Though the side effects 






side effects are important factors when determining the proper stimulus intensity, because 
tolerability limits the stimulus intensity. 
The observed side effects are consistent with the activation of vagal A and B 
fibers, but how VNS leads to the observed therapeutic effects is less clear. Considering 
the composition of the vagus nerves, which is dominated by small, slow-conducting 
axons142,143—afferent C fibers—many have suggested that the central effects (e.g. 
antiepileptic, antidepressant) of VNS are caused by activating the afferent 
pathway15,148,161,162. Because VNS can cause activation of the neurons in the NTS and 
thus influence many structures in the brain associated with the NTS, this conclusion is the 
most intuitive. In a particular study by Zabara162, the stimulus was still effective in 
suppressing motor seizures even after the vagus nerve was transected distal to the 
stimulating electrodes. However, there is no evidence that directly links therapeutic effect 
to C fiber activation. For example, vagotomy alone may have anticonvulsive effects.  
Some studies have argued that C fibers are not involved at all in the mechanism of 
VNS, and that efferent fibers (most likely B fibers) are more important for therapy (at 
least for epilepsy)163–165. In the key study backing this argument, Krahl et. al. used 
capsaicin, an excitotoxin more selective for C fibers, to destroy C fibers and eliminate C 
fiber activation. They then found that VNS is still effective in seizure suppression164. 
However, this study failed to provide electrophysiological data that C fibers were indeed 
destroyed. Also, the method used to achieve fiber-selective stimulation is not suitable for 
patient use, and so the experiment cannot be translated into the clinical setting. 
Overall, neither the Krahl et. al. study nor any other study has produced definitive 






of VNS are due to activation of a combination of nerve fiber groups. To assess how 
different fiber activation patterns changes the effects of VNS, it is necessary first to have 
methods to alter the fiber selectivity of the stimulus. 
 
3.4 Existing Methods for Selective Stimulation 
 
3.4.1 Selective Conduction Block 
It is possible to block conduction in fiber populations without chemicals. In a 
2004 article, Bhadra & Kilgore thoroughly summarized the method of blocking with 
direct current, which involves holding a nerve segment at a depolarized or hyperpolarized 
state with an extra set of blocking electrodes proximal and distal to the stimulating 
electrodes166. This technique is more effective at blocking larger fibers, as well as fibers 
near the surface. Similarly, the set of blocking electrodes can generate alternating current 
waveforms to block conduction167,168, and again, larger fibers are more susceptible. These 
electrical block methods, though less damaging to the nerve, still are not much different 
from the chemical methods. In addition, the blocking stimuli can be very energy costly, 
which is a non-trivial concern for battery-powered implants. 
Overall, conduction block is not an appropriate strategy for altering fiber 
selectivity VNS treatment, because, as mentioned before, blocking conduction in vagal 
fibers and silencing their activity will have large system-wide effects and may interact 
with or confound the therapeutic effects of VNS. Conduction block is also not a practical 






- The extra blocking electrodes would require more space and further complicate 
surgery 
- The blocking waveform would greatly increases the energy consumption 
- The impaired conduction would lead to a different set of side effects 
Therefore, it is better to control the fiber selectivity of VNS without modifying properties 
of the nerve. 
 
3.4.2 Fiber-Selective Electrodes 
Different electrode designs can produce different patterns of fiber activation 
without conduction block. Using a penetrating microelectrode array, Branner et. al. were 
able to access nerve bundles and fascicles169. Using a multi-contact electrode cuff that 
flattens the nerve, Tyler & Durand were able to achieve selectivity without penetrating 
the nerve170. Though effective, these electrodes are more invasive than the cuff and are 
not in use clinically. In addition, with these electrodes, to selectively activate target nerve 
bundles and fiber populations requires mapping different portions of the nerve to the 
different contact sites. Implementing this system requires a level of data processing and 
computation that is difficult to implement in an implantable device. 
It is also important to note that these electrodes offer only spatial selectivity. The 
multiple contacts can be used independently to activate portions of the nerve, but there is 
still no control over which types of fibers are activated. Fiber group selectivity can be 
achieved only if the individual contacts are making contact with separate fiber groups. 
However, in the vagus nerve, there is no specific spatial organization. The bundles of 






3.4.3 Fiber-Selective Stimulus Waveforms 
Achieving different patterns of fiber activation with different stimulus waveform 
designs is perhaps the best strategy. Though it may not be the most selective, this strategy 
does not create any additional disruption or damage to the nerve and does not raise much 
safety or feasibility concerns for future integration into VNS implants. Different stimulus 
waveforms can be implemented with standard cuff electrodes and without additional 
instrumentation. Finally, without conduction block, the nerve behaves in a more natural 
manner. 
In the past, stimulus waveforms with various pulse shapes have demonstrated 
adjustable fiber selectivity. Quasi-trapezoidal and quasi-triangular pulses that have a 
steep rising edge and a slow decay over millisecond scale can be designed to be selective 
for small fibers30,171–173. The reverse quasi-trapezoidal or quasi-triangular pulse (a slow 
rise with steep falling edge) can also be selective for small fibers, but it is less so than the 
normal quasi-trapezoidal pulse, and it requires more charge per phase for nerve 
activation173. Other non-rectangular pulse shapes have been investigated as well and have 
been shown to be more efficient for neurostimulation96,99, and they may also be selective 
for different fiber groups. Table 2 contains an illustration of these pulse shapes.  
However, all the non-rectangular pulse waveforms suffer from a common flaw—
they are difficult to implement in an implantable device. Rectangular pulses can be 
generated simply by switching the stimulus on and off, but non-rectangular pulses require 
the processing unit to create the digital waveform and convert it to an analog stimulus, a 






Rectangular pulse waveforms can be cleverly designed to be selective for certain 
fibers. Grill & Mortimer have shown that the activation threshold of different fiber 
groups can be altered by applying hyperpolarizing or depolarizing prepulses to condition 
the axon membrane, before delivering the stimulus pulse97,150. These pulse shapes tend to 
be stepwise ramping rectangles (see Table 2 for illustration).  
Table 2. Stimulus pulse characteristics compared to the rectangular pulse 












- -  + + + The stimulus itself requires 
more current/charge; the 
pulse generator would also 
require more energy to 











+ Unknown The stimulus itself is more 
efficient, but it incurs the 
higher pulse generator 





- - - - Intended for targeting large 
fibers. Degree of 
selectivity slightly 






-  + + Degree of selectivity 
slightly adjustable at the 
cost of efficiency. 






Hyperpolarizing prepulses, which causes the inactivation gates of the voltage-
sensitive sodium channels to open, increase the excitability of nerve fibers. Conversely, 
depolarizing prepulses, by closing the inactivation gates, decrease excitability and 
increase activation threshold. Because large fibers respond more to electrical 
stimuli24,58,97,150–152, which applies to the prepulse as well, the prepulses affect the 
activation threshold of large fibers more, and the stimulus can be designed to be more or 
less selective for large fibers. Though this type of stimulus waveform is not as effective 
as quasi-trapezoidal waveforms in eliminating the larger fiber response173, it is more 
easily implemented with a stimulator, and it has the extra ability to increase the 
selectivity for large, fast fibers. 
Second, because the prepulses are low-intensity stimuli, they only affect fibers 
near the surface; deeper fibers have normal activation thresholds97,150. When aiming to 
activate large portions of the nerve, a stronger pulse must be delivered to recruit deeper 
fibers, and so a stronger prepulse must be also delivered to condition the deeper fibers. 
However, increasing the prepulse duration would decrease the change in activation 
threshold150, while increasing the amplitude may cause the prepulse to be suprathreshold. 
Therefore, the prepulse strategy is only valid for lower nerve activation levels. 
Finally, despite using long pulses with low amplitudes, the prepulses are still 
capable of activating large, fast fibers. As reported by Vuckovic et. al., a 0.31mA, 0.8ms 
depolarizing prepulse did not activate any fibers in the pig vagus nerve, but a 0.4mA, 
0.8ms prepulse did activate a portion of the Aβ fibers
173, the fastest subgroup of A fibers. 
The 4mA, 0.2ms stimulating pulse that followed the suprathreshold 0.4mA, 0.8ms 






nerve response to the subthreshold 0.31mA, 0.8ms prepulse plus the 4mA, 0.2ms 
stimulating pulse is about the same as the response with a rectangular pulse. In fact, it 
seems that it is because portions of the Aβ fibers were activated by the prepulse and thus 
refractory that the stimulating pulse activates fewer fibers. In essence, when prepulses are 
applied to condition the fiber groups to a stimulus pulse, the large fibers may fire two sets 
of action potentials for every one set of small fiber action potentials. As a result, it is 
difficult to maintain the frequency of the stimulation and ensure consistent nerve 
response when changing the prepulse parameters. 
With electrical stimulation, overall selectivity is low, and even minor shifts in 
selectivity may lead to significant effects. Table 2 provides a summary of the 
characteristics of the relevant stimulus waveforms. It compares the efficiency of the 
waveforms at activating nerve fibers and the fiber selectivity, using the rectangular pulse 
as the standard. 
 
3.5 Introducing Burst-Modulated Stimulus Waveforms 
Because of the flaws in the existing fiber-selective stimulation strategies, I 
developed a different method of designing stimulus waveforms, termed burst modulation. 
In contrast to standard rectangular pulse waveforms, which are created by repeating 
rectangular pulses with defined pulse width (PW) and amplitude (AMP, could be voltage 
or current), burst-modulated waveforms are created by repeating bursts of much narrower 
pulses, termed “pulsons”. Pulsons can be rectangular in shape as well, so that they can be 
generated in the same simple on-off, switch-like manner. An example of burst-modulated 






When a pulse is to be delivered, the stimulator generates a burst of pulsons in 
place of a single rectangular pulse. In burst modulation, only the pulse shape is replaced; 
other stimulus parameters such as stimulation frequency and train duration are not 
modified. For a burst of pulsons, each pulson has a defined pulson width (pWx, x 
denoting the pulson number in the burst) and amplitude (ampx). The interpulson interval 
(IpIx) defines the interval between successive pulsons Number of pulsons (Nop) refers to 
the number of pulsons within the burst. There are also two derived parameters that are 
useful for characterizing these waveforms: effective PW and burst duty cycle. These 
terms and definitions are based on those for the standard rectangular pulse. 
 
Figure 9 Rectangular pulse and burst-modulated waveforms. A comparison of the 
standard rectangular pulse waveform and a 2-pulson burst waveform, with stimulus 
parameters annotated. Both are biphasic, cathode-leading, charge-balanced waveforms 
with the same repetition frequency. In this example, IpI2 exists to simplify calculations 






The parameters, i.e. Nop, ampx, pWx, and IpIx, can all be changed independently 
in a free-form manner that allows the creation of complex waveforms. To simplify 
experimentation and analysis, all pulsons in the burst can be set to be identical (e.g. pW1 
= pW2 = pWx). Even with identical pulsons, the stimulus waveform has many more 
degrees of freedom that can be manipulated. Please see Qing et. al.174 for more details. 
 
3.6 Methods for Characterizing Burst-Modulated Waveforms 
 
3.6.1 Animals and Surgery 
Several experiments were performed to test burst-modulated waveforms against 
rectangular pulse waveforms. The experiments involved electrical stimulation of the left 
vagus nerve in rats under anesthesia. All procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) and adhered to the guidelines set for in the 
NIH Guide for the Care and Use or Laboratory Animals (Eighth Edition). 
For each experiment, a female, Long-Evans rat (275-350g) was anesthetized with 
isoflurane (induction: 5% in 2L/min O2; maintenance: 0.5- 2%). Butorphanol (1.5mg/kg 
per 4 hours of surgery) was injected subcutaneously for analgesia. A midline incision was 
then made in the ventral cervical region. By dissecting between the infrahyoid muscles 
and the sternocleidomastoid, the left carotid sheath was exposed. The left cervical vagus 
nerve is inside the sheath and was isolated from the carotid artery.  
Two two-lead cuff electrodes were wrapped around the nerve, with the distal one 
for stimulation and the proximal for recording. The stimulating electrode was placed 






recording electrode was placed above the omohyoid, slightly below the carotid 
bifurcation, around C-4 level. The typical electrode separation was 7.0mm (range 6.0-
8.0mm, measuring error ±0.25mm).  
Initially, the only rationale for having the stimulation electrode more distal/caudal 
and the recording electrode more proximal/rostral is so that the nerve response travelling 
to the brain is recorded. Because an action potential generated in the middle of an axon 
will conduct both ways, swapping the cuff positions yields the same result. However, 
because the vagus nerve may branch in the cervical region, stimulating the distal end will 
ensure that all stimulated axons are cuffed by the more proximal recording electrodes. 
 
3.6.2 Custom Electrode Design and Fabrication 
The electrodes were made in house with braided Pt10Ir microwires (an alloy with 
90% platinum and 10% iridium), 0.006 inch total diameter (supplied by Fort Wayne 
Metals), and a silicone material for the cuff (see Figure 10 for more details on the cuff). 
The microwires were only exposed inside the cuff, with an estimated contact area of 
0.011cm2 for each microwire. For each cuff, the microwires were spaced 1mm apart 
(center-to-center). The lead-to-lead impedance values of two of these electrodes were 
measured to be 0.95 and 0.98kΩ at 1kHz, and the charge storage capacity values were 4.2 
and 3.7mC/cm2.  
These capacity values are rather high compared to what others reported32, the 
reason being that the geometric area was estimated without accounting for the braiding. 






phosphate buffered saline with a Gamry Reference 600, as detailed in a study by Ward et. 
al.175, except a 50mV/sec step was used instead of 1V/sec for cyclic voltammetry. 
 
3.6.3 Experimental Setup 
For each trial of stimulation, a 1-second train of 20 pulses or 20 pulson-bursts was 
delivered (VNS is commonly set to be 20Hz in both research and clinical 
settings136,141,148,162,176), and the nerve response was recorded. All stimuli were charge-
balanced, cathode-leading, alternating monophasic waveforms. The alternating 
 
Figure 10 Cuff electrode for VNS experiments. The electrode leads are made of 
braided platinum-iridium microwires (90% Pt, 10% Ir) with total outer diameter of 0.006 
inch. The cuff material is made with a silicone tubing with an inside diameter of 
0.635mm (AM Systems 806700). The microwires are sheathed in silicone tubing (inner 
diameter, id = 0.304mm, AM Systems 806100). Exposed lead segments are threaded 
through the cuff, and then silicone adhesive (Nusil MED2-4420 or MED2-4213) is 
applied to seal the joints and insulate exposed lead segments outside the cuff lumen. The 
leads are spaced 1mm apart. Generally the cuffs are made such that the lumen opens up 
to allow the nerve to enter the lumen. The opening then can be closed by wrapping suture 






monophasic waveform, where the anodic charge-balancing phase was applied at half the 
period after the cathodic phase, allows artifact cancellation177. 
The stimulus waveforms were first generated using MATLAB. A data acquisition 
system (DAQ, National Instruments, USB-635x) converted the digital waveform into an 
analog voltage signal. A custom-made Howland current pump (with ±10V power supply) 
then converted the voltage signal into a current waveform and passed the stimulus to the 
distal cuff. The nerve response at the proximal cuff was amplified and conditioned using 
a Grass P511 preamplifier, with 1Hz – 10kHz passband, 1000 – 2000x gain, and a 60Hz 
notch filter. Through the same DAQ, the conditioned signal was digitized initially at 
50kHz. The sampling rate was lowered to 25kHz in later experiments, with no noticeable 
differences in signal quality. This experimental setup (see Figure 11) is modified from 
that in Ward et. al.177. 
 
3.6.4 Neural Activation Data Analysis 
When the stimulus was above threshold, each pulson-burst with effective PW 
shorter than the refractory period elicited only a single compound nerve action potential 
(CNAP) (see Figure 12). In our experiments, the averaged CNAP signal typically 
consisted of two large, distinct peaks. The faster peak (conduction velocity falling in the 
range of 10-27m/s) was designated as the A fiber response, and the second, slower peak 
was designated as the C fiber response (range 2.5-3.3m/s, see Table 1 and 
references145,148). Conduction velocity was calculated by dividing the electrode separation 
distance by the peak latency145,154. The height of each peak was designated as the 






peaks have a larger negative component, in which case the negative peak height is taken 
as the response magnitude. Other fiber populations and subpopulations did not produce 
prominent and consistent peaks and were excluded from analysis. 
 
Figure 11 Instrumentation for VNS experiments. (a) Hardware setup for simultaneous 
left vagus nerve stimulation and recording. The stimulation cuff is distal to the head; the 
recording cuff is proximal. The more distal lead of the stimulation cuff is always 
grounded, while the more proximal lead is the active electrode. The active electrode is 
driven both cathodically and anodically during stimulation. The more distal lead of the 
recording cuff is always the positive differential input into the Grass amplifier, and the 
proximal lead is always the negative input. With this configuration, the stimulus artifacts 
for the cathodic and anodic phases are always equal and opposite in magnitude. During a 
trial, the computer (PC) software generates a digital waveform that is converted to an 
analog voltage waveform via the DAC on the National Instruments DAQ. The voltage 
waveform is then converted into a current waveform through the improved Howland 
current pump. At the start of the stimulus, the software also triggers the DAQ’s ADC to 
sample the conditioned signal from the Grass amplifier. (b) Circuit schematic of the 
custom improved Howland current pump. The op amp OPA140 is powered by ±10V. 
Stim_V is the voltage waveform input, and Stim_I is the current waveform output, with 
R3 (1kΩ in this case) setting the gain. A blocking capacitor is placed at the output to 
prevent DC leak. The settling time for the pump is about 3μs when loaded with an 






For each waveform, the fiber response magnitudes were measured at varying 
stimulus intensities (sample responses in Figure 12). For both A and C fibers, the 
relationships between the stimulus intensity and fiber response magnitudes were 
characterized using sigmoidal recruitment curves (see Figure 13, similar methods have 














 Equation 5, 
where V, the response magnitude in μV, is a function of Q the stimulus charge per phase, 
with units in  nC; Vmin and Vmax are the asymptotes; Q50 is the charge per phase value at 
the inflection; and rate is a constant that describes the steepness of the curve and relates 
to the rate of fiber recruitment. Curve fitting was done using MATLAB. 
Vmin and Vmax correspond to the minimal and maximal response magnitude, 
respectively. Rather than assuming it is 0, Vmin is determined by delivering zero-
amplitude stimuli. With no charge injection, the resulting nerve recording captures only 
noise and baseline nerve activity, and the root mean squared voltage (Vrms) of this 
recording is set to be the Vmin. For stimuli with non-zero amplitudes, CNAP peaks in the 
A and C fibers latency ranges that have peak heights lying outside the 95% confidence 
interval of the noise/baseline peak heights are considered above threshold. All sub-
threshold CNAP peaks are set to be Vmin. 
Response magnitudes were then normalized by first subtracting Vmin and then 
dividing by Vmax, yielding recruitment curves based on activation levels (illustrated in 






population that is elicited by a stimulus, and using fiber activation instead of response 
magnitude accounts for variability in Vmax across animals. 
There also seemed to be variability in Vmax across waveforms within the same 
animal, and the fiber recruitment models suggest that some waveforms were capable of 
reaching higher Vmax than that of the continuous pulse (as shown in Figure 13). As a 
result, magnitudes were all normalized to the Vmax of the continuous pulse. For example, 
 
Figure 12 Example processed nerve responses during stimulation trials. The stimulus 
waveform (Nop 2, pWx 20μs, IpIx 80μs) was delivered at varying current amplitudes in 
random order. For each trial, a 1-second, 20Hz train was delivered. After the artifact was 
eliminated177, the individual CNAP responses for each stimulus (thin traces) were 
averaged (thick trace, n=20 stimuli). All traces are shown from time 0 to 6ms. The top 
trace corresponds to an amplitude of 0, the bottom 1mA, and the traces in between are 
arranged in increments of 0.2mA. Peak latencies and heights (o’s) and widths at half peak 
height (x’s) were extracted from the averaged signal. Within each trial, the individual 
heights of the fiber peaks did not exhibit any order effect or deviation from a normal 
distribution, e.g. the peak height did not decrease with subsequent stimuli. The peaks 
labeled for the 0mA trial are due to noise and baseline activity. These peaks are not 






the Q50 of a waveform is the charge required to activate 50% of the maximal response 
achievable with the continuous pulse. 
The charge per phase values, rather than current amplitudes, is used to 
characterize stimulus intensities for recruitment curves. Amplitudes can be used to model 
recruitment curves as well, but when using waveforms with different pulse shapes or, in 
this case, burst-modulated waveforms, the amplitude is insufficient for describing the 
 
Figure 13 Fiber recruitment curves for selected pulse waveforms. Left plots, the 
response magnitudes for A and C fibers were extracted from CNAP responses and 
plotted against the stimulus charge per phase value. Each data point represents a single 
trial of 20 pulses/pulson-bursts. The data points follow a sigmoidal curve (R2 generally > 
0.9). All data shown are from the same nerve, same animal. Vmax is the estimated 
maximal response achievable with a certain waveform and can differ with each 
waveform. Peak magnitudes from sub-threshold stimuli are assigned the Vrms of the 
noise floor. Right plots, response magnitudes are normalized to the Vmax of the 
continuous pulse, after subtracting Vrms, for each respective fiber group. Q50 values are 
calculated from these normalized activation levels. The legend only shows the anodic 
phase of the waveform. All waveforms in the experiment are alternating monophasic. 
“Chopped” refers to a simple way to generate burst-modulated waveforms by dividing a 






pattern of charge injection. Moreover, the stimulus charge per phase is more closely tied 
to energy consumption and battery life in implants. 
Because the fiber recruitment rates can differ, as can be seen in Figure 13, both 
the efficiency and selectivity of a waveform are dependent on the fiber activation level. 
For example, the waveform with the lowest Q50C is the most efficient at activating C 
fibers to 50%, but it may not be the most efficient one at 75%. Fiber recruitment curves 
give a more complete representation of the nerve’s response than strength-duration or 
charge-duration relationships. Recruitment curves can also describe strength-duration or 
charge-duration relationships (Mollet et. al.178demonstrated how fiber recruitment curves 
can be used to construct strength-duration curves). 
Statistical analyses of nerve response data for comparing the waveforms were 
performed using SAS 9.3. 
 
3.7 Differences between Pulse and Pulsons 
To find the relationship between each burst modulation parameter and efficiency, 
different free-form waveforms at varying intensities were delivered in random order. 
Because the results from the chopped pulse experiments suggest that the 2-pulson/20μs 
pWx (chopping a 200μs pulse with 2 pulsons at 20% yields 20μs per pulson) combination 
behaves most differently from the continuous pulse, the 2-pulson/20μs pWx waveform 
was selected as the starting point. Fixing the Nop at 2, the pWx was set at 20, 30, and 
then 40μs. Then fixing the pWx at 20μs, the Nop was set at 2, 3, and 4. At each Nop-
pWx combination, the IpIx was set to 0, 10, 20, 40, 100, and 200μs (note, waveforms 






Pulson-bursts longer than 1ms (longer than the refractory period) are excluded from 
analysis because multiple action potentials were elicited (example in Figure 14).  
The Q50A and Q50C for all waveforms and animals are summarized in Figure 15. 
To assess how burst modulation parameters affect efficiency, the effects of Nop, pWx, 
and IpIx on Q50A and Q50C are tested using multiple linear regression, in the form: 
 





where Q50 (Q50A or Q50C) is the response variable; Nop, pWx, and IpIx are the predictors, 
with their corresponding β’s being the regression coefficients; Danimal is the dummy 
variable matrix for the animals, and δanimal is the corresponding coefficients; and ε is the 
error term. Regression analysis establishes a quantitative relationship between each burst 
modulation parameter and fiber recruitment characteristics, allowing prediction and 
interpolation of fiber recruitment based on a continuum of parameter values. 
 
Figure 14 Example CNAP response for IpIx = 1ms. The type of data is the same as 
shown in Figure 12. The waveform used was a 2-pulson burst with pWx = 20μs and IpIx 
= 1ms. For this particular trial, the stimulus artifacts were not cancelled completely. The 
sharp artifact near 0 and 1ms mark where the pulsons were delivered. Immediately 
following each artifact is an A fiber response, which is then followed by a second one 
smaller in magnitude than the first (due to the relative refractory period). The C fiber 
response peaks from the two pulsons overlap with each other. Reprinted © 2015 IEEE. 
























The regression results (Table 3 & Table 4) suggest that both Q50A and Q50C 
increase with increasing Nop, pWx, and IpIx (the p-values for all three coefficients were 
< 0.0001 for Q50A and Q50C; residual diagnostics confirmed the regression assumptions). 
That is, the charge per phase required to reach 50% A and C fiber activation increases 
with increasing Nop, pWx, and IpIx. Among these three parameters, Nop had the most 
effect on Q50, followed by pWx and then IpIx. 
 
Figure 15 Q50A, Q50C, and level of A fiber activation at Q50C for all waveforms. Q50 
values and A fiber activation levels were calculated from recruitment curves for both A 
and C fibers. The Nop, pWx, and IpIx parameters are annotated below the box and 
whiskers, the units for pWx and IpIx being μs. Waveforms with IpIx = 0 were treated as 
continuous waveforms with PW equal the report Nop multiplied by the pWx. n = 3-6 
animals for each waveform (low variability for some waveforms is due to having n = 3 






Table 3. SAS output for multiple regression of Q50A and burst modulation 
parameters 




t Value Pr > |t|  
  (p-value) 
Intercept 1 -3.11132 1.61212 -1.93 0.0558 
Nop 1 4.51615 0.42546 10.61 <.0001 
pWx 1 0.12007 0.02056 5.84 <.0001 
IpIx 1 0.04587 0.00363 12.65 <.0001 
R91dummy* 1 18.71064 0.87672 21.34 <.0001 
R93dummy 1 15.79666 0.87055 18.15 <.0001 
R94dummy 1 -2.88756 0.74810 -3.86 0.0002 
R97dummy 1 1.76400 0.74810 2.36 0.0198 
R101dummy 1 7.60904 0.87055 8.74 <.0001 
* The dummy denotes the variables of the dummy matrix. P-value for dummy variables 
simply signify that activation profiles differ among the animals. Reprinted © 2015 IEEE. 
 
Table 4. SAS output table for multiple regression of Q50C 




t Value Pr > |t| 
  (p-value) 
Intercept 1 0.56723 1.06815 0.53 0.5963 
Nop 1 3.42476 0.28190 12.15 <.0001 
pWx 1 0.09858 0.01362 7.24 <.0001 
IpIx 1 0.02722 0.00240 11.33 <.0001 
R91dummy 1 6.68427 0.58089 11.51 <.0001 
R93dummy 1 10.12777 0.57680 17.56 <.0001 
R94dummy 1 -3.86533 0.49567 -7.80 <.0001 
R97dummy 1 0.65962 0.49567 1.33 0.1856 
R101dummy 1 8.46077 0.57680 14.67 <.0001 
Reprinted © 2015 IEEE. 
The estimated A fiber activation at Q50C was used to compare fiber selectivity 






and C fibers, it is possible to interpolate A and C fiber activation based on a chosen 
stimulus intensity. This intensity could be some arbitrary value, e.g. 20nC, or it could be 
more empirically chosen and based on the recruitment curves, such as Q50. When 
stimulating the nerve at Q50C, the expected C fiber activation would always be 50% with 
minor variability regardless of waveform, but the A fiber response may differ 
significantly with waveform. In addition, the Q50C value may differ with waveform due 
to differences in efficiency. 
Using the recruitment curves derived from the parametric analysis, the level of A 
fiber activation at Q50C for all waveforms are calculated (plotted in Figure 15). The 
effects of Nop, pWx, and IpIx on the A fiber activation are then tested using, again, 
multiple linear regression, by using the same regression model as described in Equation 
6, except the Q50 term is replaced with A fiber activation at Q50C. 
The regression results (see Table 5) show that, while maintaining 50% C fiber 
activation, only changing the IpIx has an effect on the level of A fiber activation. For all 
animals, increasing the IpIx is correlated with a decrease in A fiber activation (p < 0.0001 
for IpIx; p = 0.2019 for Nop; and p = 0.8176 for pWx; residual diagnostics confirmed the 
regression assumptions). Though Nop and pWx do not seem to affect selectivity directly, 
there may be significant interaction effects. 
As an example, Figure 16 demonstrates the effect of varying only IpIx on the 
CNAP response. As IpIx increases, the activation levels for both A and C fibers decrease, 
consistent with the efficiency regression results. And interestingly, with each increase in 
IpIx, A fiber activation decreases more than C fiber activation, which suggests that the 







Table 5. SAS output table for multiple regression of A fiber activation at Q50C. 




t Value Pr > |t| 
  (p-value) 
Intercept* 1 0.56486 0.06959 8.12 <.0001 
Nop 1 -0.02355 0.01836 -1.28 0.2019 
pWx 1 -0.00021 0.00089 -0.23 0.8176 
IpIx 1 -0.00072 0.00016 -4.61 <.0001 
R91dummy 1 -0.43002 0.03784 -11.36 <.0001 
R93dummy 1 -0.29535 0.03758 -7.86 <.0001 
R94dummy 1 -0.24608 0.03229 -7.62 <.0001 
R97dummy 1 -0.10110 0.03229 -3.13 0.0021 
R101dummy 1 0.10665 0.03758 2.84 0.0053 
* The A fiber activation at Q50C should be non-zero. Reprinted © 2015 IEEE. 
The results from comparing different burst-modulated waveforms and rectangular 
pulse waveforms suggest that waveforms with short duration of charge injection (short 
PW or short pWx) were more charge efficient, requiring less charge to reach 50% fiber 
activation. This observation is consistent with modeled and empirical charge-duration 
relationships in literature, which all show increasing threshold charge with increasing PW 
in an almost linear manner (Weiss’s formula)33,47,48,50,67. 
The results also suggest that waveforms without IpIx were more A-selective. The 
fiber recruitment profiles show that intervals added during a pulse, i.e. inter-pulson 
intervals, can decrease A fiber activation. This observation is also consistent with the 
established notions that 1) short-PW stimuli yield lower thresholds for fibers with larger 
diameters24,58,151, and 2) sensory fibers and slow-conducting fibers have longer strength-







Regression analysis aside, the lowest Q50C in the data set shown in Figure 15 was 
11.49nC (mean of n=6 animals), which resulted from the single 40μs pulse. This 
observation reiterates that short pulses are the most efficient. For this efficient, single 
40μs pulse, A fiber activation was 38.7% (mean of n = 6) at Q50C. In contrast, at Q50C, 
the lowest A fiber activation level for burst-modulated waveforms was just 12.8% (mean 
of n=4 animals), which was from a 3-pulson waveform with pWx of 20μs and a long IpIx 
 
Figure 16 CNAP responses to burst-modulated waveforms. A and C fiber activation 
are compared for various waveforms, annotated in figure. The repetition frequency for all 
waveforms was 20Hz, train duration was 1 second (n=20 stimuli per trace), and current 
amplitude was 0.24mA. For simplicity, only the averaged trace is plotted. At the same 
amplitude, the A and C fiber response magnitudes to a single pulse of 40µs are the 
lowest. With 2 pulsons and IpIx = 0 (80µs pulse), the magnitudes are highest. As the IpIx 
increases in duration, both A and C fiber responses decrease, and A fiber magnitude 
decreases more than the C fiber magnitude. Note: when the A fiber response contains a 
notably larger negative deflection, the case for this animal, the negative deflection was 






of 200μs. The lowest A fiber activation when using single rectangular pulse waveforms 
was 35.0% (mean of n = 6 animals). So overall, the single rectangular pulse waveforms 
are not as selective for C fibers. 
However, the 3-pulson waveform, though more selective for C fibers, was not as 
efficient, with Q50C = 19.6nC. The most C-selective rectangular pulse waveform was the 
80μs pulse waveform, with Q50C = 13.2nC and 35.0% A fiber activation. These results 
are all consistent with the regression analysis: a short pulse with no IpIx is efficient, but a 
pulson-burst with long IpIx tends to be more selective for C fibers. 
 
3.8 Proposed Mechanism of Action for Burst-Modulated Waveforms  
As long as the entire burst duration is shorter in duration than the refractory 
period, each pulson-burst can only elicit a single action potential and behaves like a 
single continuous pulse. This method of supra-refractory charge delivery creates a charge 
buildup at the axon membrane in a manner not unlike temporal summation at the synapse. 
With the first pulson, fibers that depolarize beyond the threshold membrane voltage will 
fire action potentials, and these fibers will be in the refractory period. When the next 
pulson is delivered, the refractory fibers cannot respond, but a portion of fibers that did 
not activate during the first pulson will fire. The same will be true for subsequent pulsons. 
For the fibers that have not fired, because they were partially depolarized by 
previous pulsons, these fibers are in a state of decreased excitability. The partial 
depolarization causes the inactivation gates of the voltage-gated sodium channels to close, 
so that further depolarization results in activation of fewer fibers. Because A fibers are 






fiber excitability more, which would explain the lower A activation produced by pulson-
bursts. The mechanism is similar to that for the pre-pulse introduced by Grill & 
Mortimer97,150. The major difference between pulsons and prepulses is that, unlike 
prepulses, pulsons do not need to be subthreshold, so each pulson can contribute to nerve 
activation in addition to conditioning the nerve. 
The higher charge efficiency is due to the fact that the stimulus charge is 
delivered as narrow pulsons (microseconds to tens of microseconds). Because pulsons are 
generally much shorter than a rectangular pulse, at the same charge level, the pulsons are 
much higher in amplitude. Therefore, consistent with the principle that short PW pulses 
are more efficient33,47,48,50,67, each pulson is highly effective at activating nerve fibers.  
Though not included in the experiments presented earlier, each pulson in the burst 
can have different parameters (e.g. pW1 ≠ pW2), creating complex patterns of charge 
injection that may be used to further improve efficiency and selectivity. For example, by 
using hyperpolarizing pulsons before depolarizing pulsons, it may even be possible to 
increase A fiber selectivity by similar mechanisms proposed by Grill & Mortimer97,150. 
 
3.9 Implementation of Burst-Modulated Waveforms  
Burst modulation provides more control over the stimulus waveform by 
introducing a different set of parameters. The larger parameter space is useful for fine-
tuning the tissue response, but it also makes parameter selection more difficult. For 
rectangular pulse waveforms, there are only two parameters—PW and AMP. In contrast, 
for burst-modulated waveforms, there are four—Nop, pWx, IpIx, and ampx. In the 






long versus short pWx or IpIx. The parameters are then randomly combined to create 
various stimulus waveforms. This type of parametric sweep is a rather brute-force 
approach, but it does quickly yield recruitment profiles useful for comparing different 
waveforms. This parametric sweep process is also subject-specific and can serve as a 
calibration procedure. 
After the parametric sweep, instead of using regression to find the relationship 
between the stimulus and the nerve response for a population of subjects (see Equation 
6), analysis can be focused on the individual subject to profile the neural response for the 
parameters. The stimulus-response relationship then can be used to predict the individual 
subject’s response profile for the entire parameters space. This profile can also be 
updated with future stimulation trials and parametric sweeps to improve its prediction 
accuracy and to allow it to adapt to changes over time. 
In addition to improving efficiency of fiber recruitment, another advantage of 
burst-modulated waveforms is that the on-off nature of the waveform is easy to 
implement in implantable stimulators. It is more difficult, as well as more processing 
intensive, to generate the more complex waveforms, such as trapezoidal, step-functions, 
and sinusoidal pulses. For example, by using one additional switch, the processor unit of 
the implant would be able to generate pulson-bursts instead of standard rectangular pulses. 
In fact, there are existing systems capable of generating burst-modulated waveforms179. 
 
3.10 Conclusion 
In the experiments described in this chapter, each animal responded differently to 






(even after normalizing the response magnitudes, high variability is apparent in Figure 
15 and the regression results). In the clinic, patients are likely to exhibit different nerve 
response as well, even though the implant, the surgery, and the stimulus, in addition to 
other factors, are controlled carefully. The variability in the nerve response is a likely 
contributor to the variability of the effectiveness in patients.  
By adding a set of recording electrodes, the nerve’s response to the stimulus can 
be characterized in an objective manner. This objective response monitoring is the 
essence of ANC. Combining the response feedback of ANC with the systematic method 
of designing and analyzing burst-modulated waveforms, the nerve’s response profile to 
different waveforms can be quickly captured. With those response profiles, the stimulus 
can be adjusted to create the optimal nerve response profiles. 
A VNS system with ANC and burst modulation integrated can be used for 
studying the mechanism of VNS, pinpointing the fiber group(s) involved. At the same 
time, if the target fiber group(s) is known, the same system will enable optimization of 
stimulus selectivity and/or efficiency for each subject, boosting efficacy while reducing 
side effects and complications. 
 
3.11 Notes 
With permission from IEEE TNSRE, some portions of the texts and several 
figures in this chapter were reproduced and adapted from the manuscript Qing et. al.174, 
© 2015 IEEE, which contains my original work. The manuscript contains a thorough 







CHAPTER 4. ACTIVATION CONTROLLED VNS 
4.1 Introduction to Activation Control 
CHAPTER 3 presented a new method of achieving higher fiber selectivity with 
electrical nerve stimulation. The foundation this new method is built on a new paradigm 
of neurostimulation that will be referred to as activation control. Currently, neural 
stimulation (be it in the brain, spinal cord, or peripheral nerves) is performed in an open-
loop fashion, where the neural response to stimulation (even when recorded180) is usually 
ignored, and the physiological effects of stimulation is correlated directly to the stimulus. 
This standard stimulation paradigm will be referred to as stimulus control.  
In contrast, activation control involves correlating the physiological effect to the 
neural tissue response, not the stimulus. In the brain, the response could take the form of 
spike activity or evoked potentials, and in nerves, the response would be CNAP. The 
same stimulus does not create the same response in subjects; the same stimulus may not 
even create the same response in the same subject at all times. Mapping the stimulus to 
the response will eliminate many factors that can lead to variability, such as electrode 
properties, discrepancies due to surgery, biological differences, and changes over time. 
Activation control, then, produces much stronger, reliable correlations. After all, when a 
neuron is stimulated, it is the resulting action potentials travelling toward the synapse that 






In CHAPTER 2, the brain response data to DBS were lacking, and so setting the 
parameters was arbitrary. This stimulus control paradigm is rather hit or miss. That the 
200μA group experienced a sustained reduction in alcohol intake involved a bit of luck. 
The VNS experiments in CHAPTER 3 were comprised of building quantitative 
relationships between the stimulus and the nerve response, and this chapter will 
demonstrate how the nerve response affects physiology. 
In the case of the vagus nerve, stimulation of the A (mostly motor efferent) and B 
(mostly parasympathetic) fibers causes obvious physiological effects (discussed in 
Chapter 1). Of all the various function of the vagus nerve, its effects on the heart are 
perhaps the best characterized and have the most clinical significance. The experiments 
summarized in this chapter involve activation-controlled stimulation of the vagus nerve. 
These experiments aim to demonstrate that the cardiac effect of VNS can be better 
correlated to the nerve response rather than the stimulus parameters. The results have 
important implications for the delivery of VNS in patients with epilepsy as well as 
patients with cardiovascular disease. 
 
4.2 Vagus Nerve and Heart Disease 
The effects of vagus nerve on the heart have been studied for a long time, dating 
as far back as the late 1800s181. And unlike the antiepileptic effects of VNS, the major 
autonomic functions of the vagus nerve have been well characterized. As mentioned in 
Section 3.3, the parasympathetic efferents of the right vagus nerve mostly decrease heart 
rate and contractile force, and those of the left vagus nerve mostly decrease nodal 






impact on the heart, which is why VNS implants for epilepsy only stimulate the left 
vagus. However, researchers are now attempting to harness the cardiac effects of VNS 
and have begun experimenting with using VNS to treat cardiac disease. This time, the 
parasympathetic fibers of the right vagus nerve are the target.  
Heart failure is a very common condition with high morbidity and mortality. In 
the US alone, the incidence is 550,000 patients per year, and the prevalence is 5 million. 
A chronic, incurable condition, heart failure requires billions of dollars to treat annually 
and results in high numbers of hospitalizations. More than 50,000 patients die each year 
from heart failure, and due to an aging population, these figures are expected to increase 
over time182.  
Once the heart cannot adequately provide sufficient output, commonly due to 
myocardial infarction and scar formation, the autonomic tone of the body shifts to 
sympathetic overdrive. Sustained sympathetic dominance, which can manifest as 
increased resting heart rate, higher blood pressure, etc., increases the workload and 
energy demands of the heart, which is in turn damaging to the heart and leads to a 
downward spiral of cardiac function loss182.  
The standard treatment for heart failure is using pharmaceuticals such as beta-
adrenergic receptor blockers to block the sympathetic system, in addition to using 
inhibitors of the renin-angiotensin-aldosterone system, which help to decrease blood 
pressure and prevent deleterious cardiac tissue remodeling182. The standard treatment, 
however, has limited effectiveness, and mortality is rising even though treatments are 






sympathetic activity and reduced vagal activity are associated with higher morbidity and 
mortality, VNS offers a unique potential solution for achieving that balance183–187.  
 
4.3 Epilepsy, Vagus Nerve, and Heart Disease 
Aside from its antiepileptic effects, VNS as of late has shown promise for treating 
epilepsy in a way very similar to its investigative use in heart failure. Epilepsy is a 
serious condition that, in addition to seizures, manifests with a wide range of systemic 
effects. Not as prevalent as heart failure, epilepsy nonetheless afflicts as many as 1% of 
the population188, and mortality in patients with epilepsy is 1.3 to 9.3 times higher than 
the general population189. Though most patients with epilepsy die of causes not directly 
linked to seizures, such as brain tumors, infections, and suicide, sudden unexpected death 
in epilepsy (SUDEP) accounts for a significant, increasing (increasing because diagnosis 
of SUDEP has improved) amount of deaths due to seizures188,190–192. Moreover, patients 
with more severe and/or treatment-resistant epilepsy are more likely to encounter SUDEP, 
and SUDEP rates are particularly high in the younger population191–193. 
SUDEP is a fatal event, the only effective treatment being resuscitation. 
Monitoring for seizures and cardiac arrest are helpful for detecting and perhaps predicting 
SUDEP, which can aid resuscitation efforts. The key to reducing SUDEP incidence lies 
in prevention. Adequate antiepileptic treatment with proper seizure control will 
effectively reduce the likelihood of SUDEP, as SUDEP risk increases with frequency and 
severity of seizures191–193. In this manner, VNS helps to reduce SUDEP. Recently, a new 






Evidence gathered over decades suggests that patients who died of SUDEP tend 
to have heart disease. Autopsy of patients who succumbed to SUDEP consistently 
revealed enlargement and edema of heart, lungs, and liver194, all signs of congestive heart 
failure. In addition, autopsy results showed signs of heart disease, including 
atherosclerosis and most importantly, myocardial fibrosis195–197. In addition, for patients 
<65 years of age living with epilepsy, the risk of dying from heart disease is significantly 
higher than the general population198. Overall, in patients with epilepsy, incidence of 
myocardial infarction and sudden death are significantly higher as well, so is mortality 
from ischemic heart disease198. 
Considering that patients with epilepsy and patients who die from SUDEP tend to 
be younger than those in the general population who develop heart disease, the cardiac 
findings are all suggestive of repeated cardiac insults linked to epilepsy. During seizures, 
patients can experience various cardiorespiratory abnormalities, including tachycardia, 
bradycardia, even arrhythmias, signs of ischemia, even asystole and apnea199–203, all of 
which can contribute to deterioration of cardiac function.  
In fact, patients living with epilepsy do show signs of cardiac dysfunction and 
disease. Resting heart rate tend to be higher among patients with epilepsy, and 
interestingly, patients who are at higher risk of SUDEP had higher heart rate and more 
ECG abnormalities204. Much like patients suffering from heart failure, patients with 
epilepsy have autonomic dysfunction; more specifically, they also suffer from 







4.4 VNS for Treating Autonomic Dysfunction  
For patients with epilepsy, controlling seizures is top priority, because patients 
who respond to treatment and have fewer, less severe seizures tend to have lower 
mortality and fewer complications. For treatment-resistant patients, in the past few 
decades, VNS has served a relatively effective supplemental therapy. In treating epilepsy, 
VNS has been limited to the left vagus nerve to avoid harmful cardiac effects. With the 
connection between epilepsy and heart disease becoming ever stronger, particularly in the 
case of SUDEP, stimulation of the right vagus nerve is beginning to gather attention207. 
Now, right-side VNS is being investigated to directly affect the heart, to protect it 
from heart failure and seizures. Clinical studies studying the efficacy of right-side VNS in 
treating patients with heart failure have produced promising results183,184,208. There is also 
currently a large clinical study being performed to assess the direct link between restoring 
autonomic tone with VNS and treating heart failure209. In 2014, Schomer et. al. reported a 
clinical study that directly aimed to reduce interictal cardiac instability in patients with 
drug-resistant epilepsy by stimulating the right vagus nerve207. Right-side VNS in this 
study, in addition to reducing seizure activity, was able to improve vagal tone. 
The common rationale behind VNS for heart failure and epilepsy is to restore 
autonomic balance by increasing parasympathetic vagal activity. In two of the heart 
failure studies183,184, patients undergoing VNS exhibited improvements in physiological 
and clinical indicators, such as lower resting heart rate and higher ejection fraction, as 
well as in the reported quality of life. In the third, a more recent study208, patients 






progression as compared to control. Two of the heart failure studies184,208 reported that 
chronic VNS seemed to have led to improvement of parasympathetic tone.  
In all these studies, the method for determining the stimulus parameters was the 
same as that used in standard VNS practice. That is, parameter adjustment is based on 
patient perception and physician’s intuition. As a result, even though parameters are 
adjusted on an individual basis, even if the clinical response is used as a feedback, patient 
response is highly variable. In the 2008 Schwartz et. al. study183, of the 8 total patients 
undergoing VNS, 4 experienced continuing heart function improvement, but 3 received 
temporary improvement followed by deterioration, and 1 showed no improvement and 
only deterioration for the 6-month study duration. In the 2011 De Ferrari et. al. study184 
and the 2015 Zannad et. al. study208, 59% and 62% of patients showed improvement, 
respectively. In the Schomer et. al. study207 as well, the improvement of vagal tone is 
highly variable.  
Another important consideration in right-side VNS is that the side effects can be 
much more serious. The De Ferrari et. al. study184 reported serious events that are likely 
linked to the stimulus, including atrial fibrillation, hypotension, and syncope. Other side 
effects (such as cough, dysphonia, and pain) and surgery- or device-related complications 
(such as infections and lead failure) are similar to left-side VNS. And again, the biggest 
impact of side effects is that they limit the stimulus intensity.  
 
4.5 The Benefits of Activation Control 
The key theory of activation control is that the physiological effect of 






More specifically, the same stimulus can produce different neural responses in different 
subjects, and the same stimulus delivered at different times can even produce different 
responses in the same subject. Conversely, if different stimuli can elicit the exact same 
neural response, the activated axons will lead to the same physiological effect, regardless 
of stimulus pulse shape, amplitude, etc. (although, the frequency and the stimulation 
duration do matter102,141,210). 
In VNS, the activation pattern of the nerve, which manifests as a CNAP, 
determines the effect of stimulation. As discussed in Section 3.3, A fiber activation would 
lead to mostly motor contractions, and B fiber activation would lead to parasympathetic 
effects. Accordingly, activation of both A and B fibers will lead to a combination of 
motor contractions and parasympathetic effects. The effects of C fiber activation are less 
clear, however. 
In the clinical heart failure studies183,184, the experimenters reported that, when 
setting the stimulation parameters, a reduction in heart rate linked to the stimulation is 
considered therapeutic. However, the stimulus did not cause heart rate reduction in all 
patients; it was successful in 3 out of 8 patients183 and only 3 out of 32 patients184. The 
two main reasons were 1) causing intolerable side effects and 2) reaching the stimulus 
intensity limit, which seemed to have been set arbitrarily at pulse width of 1ms and 
current amplitude of 5.5mA (perhaps set by device limits).  
It seemed that the investigators did not intentionally aim to activate enough B 
fibers to cause a heart rate reduction. And much like the mechanism for epilepsy, the 






intensity is an inexact method that introduces high variability, and this way, it is difficult 
to determine which fiber group(s) is responsible for the therapeutic effects. 
By using the level of neural activation instead of stimulus parameters as the 
method of dosing, the physiological response can be controlled more accurately and more 
precisely. The benefits of this activation-controlled over the standard stimulus-controlled 
stimulation are that: 
1. the activation level is known, allowing accurate assessment of the strength 
of the stimulus and lowering the likelihood of under- or over-stimulation; 
2. the nerve response can be matched to the therapeutic and side effects, to 
determine exact relationships; 
3. the stimulation produces more consistent responses, resulting in lower 
variability and higher response rate; and 
4. different waveforms can be used to elicit different activation patterns for 
targeted activation, so as to boost efficacy while reducing side effects. 
 
4.6 Methods for Testing Activation Control 
To demonstrate the benefits of activation control, similar VNS experiments as 
those described in Section 3.6 were conducted. The experimental setup was essentially 
the same as that shown in Figure 11, except a few differences. First, there was an 
additional goal of altering cardiac function, so the right vagus nerve was the target. The 
expected effect of right-side VNS was to decrease the heart rate, and so the decrease in 
heart rate served as the physiological response. To measure the heart rate, a two-lead 






left-side VNS experiments all included an ECG recording as well, but there were no 
notable effects due to the stimulation, so the recordings were not analyzed in detail. See 
Figure 17 for a photograph that shows the electrode cuffs wrapped around the vagus 
nerve and ECG electrodes attached. Settings for signal conditioning and acquisition were 
the same as described in Subsection 3.6.3. 
The stimulus frequency remained at 20Hz, and the stimuli were still charge-
balanced, cathode-leading, alternating monophasic waveforms. Unlike before, train 
duration was 10 seconds, because others have found that the heart rate requires several 
seconds to stabilize during VNS211,212. Other train durations (e.g. 5 seconds, 20 seconds) 
were tested as well, and 10 seconds seemed to be a good balance between capturing the 
full effect and maximizing throughput. Some lower stimulus frequency (e.g. 10Hz, 5Hz) 
 
Figure 17 Animal with nerve cuffs and ECG electrodes attached. Animal is under 
isoflurane. The electrode cuffs are wrapped around the isolated vagus nerve. The distal 
cuff is for stimulation, and the proximal is for recording. The ECG leads are arranged in 
lead II configuration, with the positive lead being near the apex of the heart. The cuffs are 
an earlier version of the one shown in Figure 10. The insulation material for these cuffs 






trials were performed as well, and the only difference was that the heart rate change was 
smaller and took longer to manifest, simply because fewer stimuli were delivered in the 
same amount of time. Therefore, most of the data were collected at 20Hz. Again, 
different waveforms and current amplitudes were applied in random order. 
 
4.7 ECG Data Analysis 
The nerve signal and CNAP were processed in the same way as described in 
Section 3.6.4. The heart rate, unlike for the left-side VNS experiments, was more 
important, and so the ECG signal was more carefully processed to ensure that the heart 
rate is extracted properly. The ANC system133 contains algorithm for heart rate extraction, 
and methods detailed in this section are modified from that existing code. Figure 18 
illustrates key steps in heart rate extraction. ECG and nerve data processing was 
performed using MATLAB. 
First, stimulus artifacts were removed using a smooth function. Setting the 
number of points to smooth to 500 generally was sufficient to remove most of the artifact. 
This method of artifact removal is simple and fast, but it does distort the waveform and is 
only appropriate for determining the heart rate. Next, the smoothed ECG was normalized 
by the maximum voltage value, and the R peaks were extracted in the same manner as in 
ANC133. The intervals between successive R peaks were calculated and converted to 
instantaneous heart rate in beats per minute (bpm). During data analysis, the R peaks 
were overlaid on the processed ECG signal and checked manually to ensure proper R 







4.8 The Effects of Stimulus Parameters on the Vagal Response and Heart Rate 
In Figure 19 are two example series of CNAP signals resulting from one stimulus 
waveform at different current amplitudes. These CNAP series plots show that, 
1. there are three distinguishable fiber populations with peaks occurring at 
different latencies; 
 
Figure 18 ECG data analysis. The 10-second raw ECG signal contains large stimulus 
artifacts. The artifacts are easily removed by smoothing, though the ECG waveform is 
deformed as well. The smoothing does not affect detection of R peaks, which remains the 
prominent feature in the recording (denoted by red x’s above each peak). Each ECG trace 
and the identified R peaks are visualized and checked for accuracy. The instantaneous 
heart rate can be calculated from the intervals between the R peaks. In this example, there 






2. even though the compound action potential complexes do interfere with 
each other, which again is a limitation due to the short electrode separation, peak 
feature extraction is still representative of fiber activation; and 
3. each nerve has a distinct CNAP signal, even though the same electrodes 
and setup were used.  
To compare the right vagal CNAP response profiles for the different stimulus 
waveforms tested, fiber recruitment profiles were constructed in a similar fashion as 
described in Subsection 3.6.4. A sample set of profiles is shown in Figure 20. The trends 
seen in these profiles are consistent with the results from characterizing burst-modulated 
waveforms (see Section 3.7, also refer to Qing et. al.174). Namely, when two pulsons are 
delivered back-to-back as a single continuous pulse, the waveform is the most efficient at 
fiber recruitment, requiring the least amount of charge to reach a certain level of 
 
Figure 19 Example nerve responses at varying current amplitudes. The left plot 
contains CNAP recorded from animal R164, and the right is from R165. The overall 
CNAP morphology for the two subjects is different, even though the setup is the same. 
Each plot consists of CNAP data resulting from only a single stimulus waveform 
delivered at five different amplitudes (in random order). The red trace is from a zero-
amplitude trial, and the trace color shifts toward violet across the spectrum as the 






activation for all fibers. When an interval is added, the efficiency decreases overall, and 
the change differs among the different fiber groups, leading to a change in selectivity. 
The longer the interval is, the more the waveform deviates from the rectangular pulse. 
Although the effects of the different waveforms on the nerve are interesting, the 
more important questions are how do the waveforms affect the heart rate and how does 
the heart rate relate to the fiber activation. In the sample Figure 21, the CNAP at varying 
amplitudes are shown with their corresponding instantaneous heart rate plots. With the 
 
Figure 20 Fiber recruitment profiles for selected waveforms. The response peak 
magnitudes for A, B, and C fibers at all charge levels were converted to activation levels 
(see Subsection 3.6.4). The burst-modulated waveform with 100μs IpIx recruits fibers 
differently from the other two waveforms shown. The other two waveforms are similar in 
shape, and their recruitment profiles are similar as well. The black dashed line marks the 
50% B activation level, and the gray dashed arrows point to the estimated A and C fiber 






zero-amplitude trial, there was no fiber activation, and the heart rate was steady, with 
minor fluctuations that correspond to breathing. As the amplitude increased, fibers began 
to fire action potentials. However, the heart rate was not affected until B fibers were 
recruited, regardless of how large the A and C fiber peaks were. This observation is 
consistent with clinical cases where patients were implanted with vagal stimulators on the 
right side. These patients experienced seizure reduction without any notable cardiac 
effects213, which suggest that other fibers were activated and B fibers were not. 
To estimate the heart rate at the end of the trial, the last 5 seconds of the 
instantaneous heart rate data were averaged. Under isoflurane, the animal breathed once 
 
Figure 21 CNAP and corresponding heart rate. The CNAP plots show only the mean 
signal. The same stimulus waveform is used for all four trials shown, and the amplitude 
increases from top (zero-amplitude) to bottom (near maximal activation). Arrows mark B 






every 1 to 2 seconds, and a duration of 5 seconds, which is longer than at least 2 cycles of 
breathing, was deemed long enough to provide an accurate estimate of heart rate.  
Occasionally, when the stimulus was strong enough, the heart rate became very 
slow and irregular (see Figure 22). Not only is the induced arrhythmia and severe 
bradycardia harmful to the subject, which could affect the trials that follow, the irregular 
rhythm also makes analysis difficult. In these cases of arrhythmia, it seems that there is 
some form of conduction block, which manifests as regular P waves with some missing 
QRS and T waves (see Figure 22). Therefore, the stimulus amplitude was generally 
limited as to prevent arrhythmia and severe bradycardia. The rats generally have a resting 
heart rate of 400 bpm, which decreases and stabilizes around -350bpm under anesthesia. 
VNS trials that resulted in a heart rate lower than 200bpm or in overt arrhythmia were 
excluded from analysis. 
 
4.9 The Vagal-Heart Rate Relationship 
To study the relationship between the vagal response and heart rate, the heart rate 
is plotted against the magnitudes of the different fiber peaks in Figure 23. Data from all 
tested waveforms (rectangular and burst-modulated) were pooled to create each plot for 
each animal subject. Across all subjects, the heart rate seems to be consistently correlated 
to B fiber response, decreasing as the B fiber peak increases in magnitude. This 
correlation confirms the scientific basis of stimulating the right vagus nerve, because the 
right vagal B fibers are precisely the parasympathetic fibers that cause depression of 






In some subjects, the A and C fiber response appear to be correlated to heart rate 
as well. This apparent correlation is mostly due to the fact that the response magnitudes 
of individual fiber groups are not independent. A high-amplitude electrical stimulus of 
any waveform will activate more fibers in general, so that a when the B fiber response 
magnitude is high, C fiber magnitude is likely high as well. Another indication that A and 
C fiber activation are not directly related to heart rate is that, for B fibers, the heart rate 
decreases as soon as the peak began to appear, while for A and C fibers the heart rate is 
steady throughout most of the range of activation. Finally, the heart rate does not change 
consistently with A and C fibers across all animals, making a causal relationship unlikely. 
A total of 6 animals underwent the right-side VNS experiments, starting with 
animals R153 and R154 and finishing with animals R162 through R165. Animals R155 
 
Figure 22 Example trial resulting in arrhythmia. The ECG trace is marked with x’s 
for R peaks. Initial ECG is normal. The arrows point to several P waves without a QRS 
complex, a sign of failed conduction. As a result, the heart rate (estimated from R peaks) 







Figure 23 Right vagal CNAP and heart rate data from all animals. The columns 
represent the different fiber groups A, B, and C. The rows represent the different animals 
that underwent the experiment. * The data from R162 is more variable because the 
anesthesia method used was intraperitoneal ketamine/xylazine injections, whereas the 






through R161 were used for another, unrelated project. So, for the purpose of this series 
of VNS experiments, these 6 animals were sequential subjects. This fact is important in 
showing that the results are highly reproducible, despite the variability among the 
subjects’ CNAP responses and B fiber-heart rate relationships. 
As can be seen in Figure 23, the range of B fiber response magnitudes and the 
range of heart rate vary among animals. Normalizing the fiber response and heart rate can 
reduce the subject-to-subject variability—normalizing the fiber response to the maximal 
response magnitude to produce activation levels is the same method used in the burst-
modulated waveform study (see Section 3.6.4). However, because high-intensity stimuli 
tend to cause arrhythmia and profound bradycardia and were avoided, the maximum peak 
magnitudes were unknown. As a substitute for the true maximum, the highest magnitude 
for each fiber peak achieved during the randomized stimulation trials served as the 
maximum. For normalizing the heart rate, all data were simply normalized to the highest 
heart rate recorded. The normalized data are combined in Figure 24. 
Normalizing the variables still does not result in a reliable profile for fiber 
activation and heart rate across all subjects. Aside from not having the true maximal fiber 
response magnitudes, there is also the challenge of accounting for variability among the 
fiber response-heart rate profiles for each subject. In the data shown in Figure 23, some 
of the B fiber response-heart rate trends appear linear while others are curvilinear. 
Therefore, even though it is technically possible to combine the normalized data and 
analyze all the data together, it is difficult to create a general profile that accurately 







Figure 25 shows the heart rate against B fiber magnitude for two sample subjects 
with the individual waveforms marked. It can be seen that as the B fiber magnitude 
increases, the heart rate decreases, and though different waveforms were used, the data 
points do not deviate from the overall trend. In more general terms, the physiological 
 
Figure 24 Combined normalized data from all animals. The heart rate and fiber 
response data are normalized to the highest values encountered. Data from all 6 animals 






effect is a result of neural activation and not the exact stimulus. The fact that the effect on 
heart rate is independent of stimulus waveform highlights the benefits of activation 
control. As long as the target fiber group is activated to the desired therapeutic levels, the 
stimulus waveforms can be altered to tune the efficiency and selectivity. 
 
 
Figure 25 Example B fiber-heart rate relationships with waveforms marked. The 
heart rate and fiber response data are normalized to the highest values encountered. Data 
from all 6 animals and all tested waveforms are pooled. The figure legend for the 
waveforms is written as: <Nop>xp<pWx in ms>_p<IpIx in ms>. For example, 






4.10 The Effects of Right-Side VNS on Heart Function 
Heart rate alone can be a strong indicator of cardiac workload and can provide a 
general sense of the autonomic balance. Using ultrasound imaging, which is a relatively 
simple procedure commonly done in the clinical setting, it is possible to determine more 
important measures of cardiac function. Combining the electrographical recordings of the 
vagus nerve and the heart and the ultrasound images can paint a complete picture of the 
effect of each stimulus on the heart. 
As a pilot experiment, one animal (R166) underwent right-side VNS with 
simultaneous recordings of the vagus nerve and ECG (similar to that described in Figure 
17) as well as ultrasound imaging. Ultrasound equipment (Vevo2100, VisualSonics) and 
expertise were provided by Dr. Craig Goergen’s group. Image acquisition focused on the 
left ventricle of the heart, and image analysis yielded estimates of stroke volume, ejection 
fraction, and fractional shortening. Using the heart rate and stroke volume, the cardiac 
output can be calculated as well. See Figure 26 for an illustration of image analysis. 
 
Figure 26 Example ultrasound image processing. The left image shows the left 
ventricle in diastole with estimated chamber volume marked red; the right image shows 






The relationship between vagal CNAP peak magnitudes and the heart rate for this 
animal is summarized in Figure 27. Consistent with the results in Subsection 4.8, the B 
fiber response is strongly linked to the heart rate. The heart rate is not correlated with A 
and C fibers. The baseline heart rate is also similar to those in Figure 23. 
The stroke volume, ejection fraction, and cardiac output data are shown in Figure 
28. The stroke volume is not affected much by stimulation, but ejection fraction does 
decrease as B fiber magnitude increases. Though the stroke volume is unaffected, cardiac 
output decreases notably due to the lower heart rate. The baseline ejection fraction of 70% 
is within the normal range for rats214,215. A decrease in ejection fraction suggests a 
decrease in ventricular contractility due to stimulation, which is also consistent with what 
others have reported216,217.  
With the heart rate data alone, one can only assume that the decreased heart rate 
reflects a decreased cardiac output as well. With the additional ultrasound imaging data, 
that assumption can be confirmed. More importantly, the availability and feasibility of 
performing ultrasound imaging in the clinical setting signifies that the procedure used in 
these experiments can be translated to patient care. When setting stimulus parameters, 
 
Figure 27 R166 vagal CNAP magnitudes and heart rate. The data presented here is 
similar to those in Figure 23. Only one stimulus waveform—100μs rectangular pulse 






vagal recording, ECG, and ultrasound can all be performed, to fully capture the effects of 
each stimulus. Then the appropriate stimulus parameters to generate the optimal neural 
activation pattern can be determined. 
 
 
Figure 28 R166 B fiber-left ventricle function relationship. Left ventricle data was 
made available by Dr. Goergen’s group. The red asterisk marks an outlier trial, where a 








The contents of this chapter are being prepared for submission for publication. 
Likely, the VNS experiment with ultrasound imaging will be repeated a few more times 
to collect additional data. The tentative title is “Controlling the vagal effects on the heart 








CHAPTER 5.  CONCLUSION 
5.1 Objective, Individualized Stimulation Dosing 
The differences in the B fiber-heart rate profile among the subjects serve as a 
strong argument for the implementation of a more objective and individualized approach 
to VNS, and neurostimulation in general. The objective aspect can be achieved by 1) 
recording the nerve response to the stimulus; 2) creating a profile for the nerve response 
to the stimulus; and 3) finding the ultimate effect of the nerve activation on physiology. If 
VNS is used for seizure suppression, the physiological effect would be changes in seizure 
frequency and severity. For heart protection, in epilepsy or heart failure, the physiological 
effect would be resting heart rate and heart rate dynamics, among other indicators. In 
spinal cord stimulation, compound action potential analysis is still a valid method for 
measuring the neural response. In brain stimulation, the response would be in the form of 
evoked potentials or spike activity. This objective approach forms the foundation of 
activation control, which allows stimulation dosing based on the subject’s response, and 
can reduce subject-to-subject variability.  
The stimulus parameters are still important, but they simply are not the major 
factor in determining how the body responds. For example, if the stimulator can only 
provide a certain amount of voltage, or if the electrodes can only safely pass a certain 






stimulation (charge per phase to achieve target activation) needs to monitored as well, 
because the most selective waveform is usually not the most efficient. Draining the 
batteries too quickly will require more replacement procedures and increases the risk of 
complications. However, just for the purpose of creating a physiological effect, the neural 
response is more important than the stimulus. This fact is true at least in the case of 
stimulating the right vagus nerve to lower the heart rate. And in this case, the stimulus is 
just a means to an end—two different stimuli that can elicit a similar vagal response will 
lead to a similar drop in heart rate. 
The individualized aspect can be achieved by creating response profiles for each 
individual rather than trying to group subjects together for analysis. The group approach 
will yield a certain group response rate, because the same neural activation likely does 
not produce the same change for everyone in the group. Again using the right-side VNS 
as an example, the same level of B fiber activation in different subjects does not produce 
the same amount of heart rate decrease (see Figure 24). Dosing each individual subject 
based on the unique profile of the subject ensures that each will achieve the optimal 
balance of therapeutic effects and side effects.  
Implanting more sensors to record more physiological data is not always feasible, 
nor desirable. Without constant physiological data feedback, it would not be possible to 
perform activation-controlled stimulation. However, during patients’ clinic visits it would 
still be better to dose by the patient’s individual neural response rather than just the 
stimulus parameters. 
The objective, individualized method of neurostimulation used in conjunction 






waveforms, discussed in detail in CHAPTER 1, creates a unique stimulus dosing system. 
This dosing system first allows researchers to determine which fiber group(s) is important 
for therapy and which fiber group(s) leads to side effects. It also allows clinicians to 
determine how to activate the target group(s) in order to maximize efficacy and minimize 
side effects. Ultimately, patients should respond in a more consistent manner, and the 
overall response rate should increase. 
 
5.2 Refining DBS Parameters 
Like for VNS, DBS parameters are also set to produce the maximal clinical effect 
without causing intolerable side effects16,89,218,219. Unlike for VNS, due to its more 
invasive nature, DBS causes side effects that can be quite severe. Stimulation can 
adversely affect 1) cognition, such as causing memory and attention deficits, 2) mental 
health, such as inducing anxiety and depression, 3) speech, and 4) functions of certain 
cranial nerves218,220,221. In the study by Koller et. al., out of 25 patients, as high as 21 
reported paresthesia, and 15 reported headeaches218. 
Also unlike VNS, the therapeutic and side effects of DBS are more due to lack of 
spatial-, rather than fiber-, selectivity. In other words, enough volume of the target tissue 
must be activated to produce therapeutic effect, but activating too much volume will 
affect neighboring regions and cause side effects. For example, to reduce parkinsonian 
symptoms, the subthalamic nucleus is a common target. By modeling the electric field 
from DBS electrodes, Cameron McIntyre et. al. demonstrated the relationship between 
distance from electrode and threshold voltage for activation (recall that DBS operates 






also activates nearby fibers in the internal capsule, leading to the commonly observed 
side effects60,222. 
Therefore, increasing spatial-selectivity would increase efficacy and decrease side 
effects. Reducing electrode size can improve spatial-selectivity, but a smaller electrode 
will have a smaller potential volume of activation. The best way to achieve better spatial-
selectivity is to improve the accuracy of electrode placement, which is dependent on 
surgical and electrode advances.  
Nonetheless, activation control and stimulus optimization can still be applied to 
DBS. Recording evoked potentials in the region being stimulated and other associated 
regions in the brain can yield valuable data on the effects of the stimulus. Simultaneous 
stimulation and recording using a standard commercial DBS electrode has been 
demonstrated already223. Other methods of recording are also available94,224,225.  
Specifically, in stimulating the nucleus accumbens shell for treating alcohol use 
and other addiction disorders, the accumbens itself and the prefrontal cortex are major 
targets for recording the effect of nucleus accumbens stimulation132,224,226–228. Central and 
peripheral side effects can also be monitored. The desired level of neural response, once 
determined, can be monitored and maintained, while the stimulus waveform can be 
adjusted to fine-tune efficiency and selectivity. Similar systems can be applied to other 
applications of DBS as well, such as for treating Parkinson’s disease. Once again, even if 
this neural response feedback-driven process can only be implemented during patient 
visits, the objective, individualized dosing system still has advantages over the current 







5.3 Ideas for Future VNS Work  
So far, the VNS experiments aimed to improve stimulus design and dosing system 
have shown that the fiber selectivity, as well as efficiency, of the stimulus can be adjusted. 
The only major modification required is a set of recording electrodes. Ideally, skin 
surface electrodes would suffice, allowing clinicians to record the vagal response without 
adding more implantable components. The feasibility and reliability of recording human 
vagal responses from surface electrodes will need to be tested. 
To fully utilize the benefits of action-controlled stimulation, the stimulator would 
need to be able to generate different waveforms. Burst-modulated waveforms can be 
rectangular in shape and were specifically designed to allow easy implementation using 
microcontroller-based stimulus generators. Incorporation into commercial implants 
should be simple but still require testing. A provisional patent229 (the order of inventors 
was mistakenly submitted; Kurt Y Qing should be the first inventor) has been filed based 
on my work with burst-modulated waveforms, and there is a full U.S. patent in progress 
of being filed.  
The experiments in CHAPTER 4 characterized the effect of right vagal B fibers 
on heart rate. The next step is to characterize the physiological effect of the other major 
fiber groups. A fibers should lead to activation of laryngeal muscles. In the rat 
experiments or in future clinical studies, laryngeal electromyography would provide 
physiological data due to A fiber activation, on either the left or right side. In the rat, it 
may be difficult due to limited space. C fiber activation are more difficult to study, since 






is mostly composed of C fibers142,143,149, characterizing changes in gut motility may offer 
an objective method to measure the physiological effects of C fiber activation.  
Finally, the biggest question to answer is whether the different vagus nerve 
activation patterns can produce differences in antiepileptic effects (or heart failure, or 
other applications). I have conducted some preliminary VNS experiments attempting to 
compare the effect of different nerve activation patterns on seizure frequency and severity. 
The tetanus toxin rat model of epilepsy230,231 was used. Rats treated with an intra-
hippocampal injection of tetanus toxin develop frequent spontaneous seizures, which is 
similar to the epilepsy syndrome in human patients.  
In my experiments, animals treated with tetanus all experienced seizures, one 
even died shortly after a seizure. Seizures were detected via a differential recording 
across two cranial bone screws and confirmed via video recording (the electrographic and 
video recording system used was the Pinnacle 8200). Seizure behavior matched that 
described in literature230,231. However, the VNS produced inconsistent results, and so it 
was difficult to determine how VNS affected seizures. 
The tetanus-treated rats were implanted with two vagal cuffs (same as shown in 
Figure 10). Immediately after implantation, it is possible to stimulate the nerve and 
record a convincing CNAP response. The impedance across the two leads of the cuffs 
increase over time, as measured by electrochemical impedance spectroscopy (same 
methods used as described in Subsection 3.6.2). The increase is expected due to natural 
tissue scarring, and the electrodes stay viable even months after implant. The longest 
implant period is 68 days, and in this animal, the recording cuff impedance at 1kHz 






stimulation cuff increased from 1.7 to a maximum of 13.7kΩ. However, the vagal signal 
deteriorates over time, and a few days after surgery, it is no longer possible to elicit a 
CNAP response.  
The problem likely lies in the physical properties of the nerve cuffs. Unlike the 
commercial ones, which are self-sizing, the custom cuffs are rather stiff and do not self-
size. It could be that over the course of days, due to continued movements of the animal 
and scar tissue formation, the electrode leads lost close contact with the nerve. It is even 
possible that tissue swelling and scarring from healing, along with irritation from the cuff 
due to movement, led to nerve degeneration. A more sophisticated, sizing cuff electrode 
is required to preserve vagus function and excitability. Only then can chronic VNS 
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séances mémoires la Société Biol. 67, 280–283 (1909). 
36. Lilly, J. C., Hughes, J. R., Alvord, E. C. & Galkin, T. W. Brief, noninjurious 
electric waveform for stimulation of the brain. Science 121, 468–9 (1955). 
37. Bard, A. J. & Faulkner, L. R. Electrochemical Methods: Fundamentals and 
Applications. (John Wiley & Sons Inc., 2001). 
38. Cogan, S. F. Neural stimulation and recording electrodes. Annu. Rev. Biomed. Eng. 
10, 275–309 (2008). 
39. Randles, J. E. B. Kinetics of rapid electrode reactions. Discuss. Faraday Soc. 1, 11 
(1947). 
40. Grill, W. M. & Mortimer, J. T. Electrical properties of implant encapsulation tissue. 
Ann. Biomed. Eng. 22, 23–33 (1994). 
41. Williams, J. C., Hippensteel, J. A., Dilgen, J., Shain, W. & Kipke, D. R. Complex 
impedance spectroscopy for monitoring tissue responses to inserted neural 







42. Polikov, V. S., Tresco, P. A. & Reichert, W. M. Response of brain tissue to 
chronically implanted neural electrodes. J. Neurosci. Methods 148, 1–18 (2005). 
43. Biran, R., Martin, D. C. & Tresco, P. A. Neuronal cell loss accompanies the brain 
tissue response to chronically implanted silicon microelectrode arrays. Exp. Neurol. 
195, 115–26 (2005). 
44. Wei, X. F. & Grill, W. M. Impedance characteristics of deep brain stimulation 
electrodes in vitro and in vivo. J. Neural Eng. 6, 046008 (2009). 
45. Lempka, S. F., Miocinovic, S., Johnson, M. D., Vitek, J. L. & McIntyre, C. C. In 
vivo impedance spectroscopy of deep brain stimulation electrodes. J. Neural Eng. 
6, 046001 (2009). 
46. Lasia, A. in Modern Aspects of Electrochemistry (eds. Conway, B. E., Bockris, J. 
& White, R. E.) 32, 143–248 (Kluwer Academic/Plenum Publishers, 1999). 
47. Geddes, L. A. & Bourland, J. D. The strength-duration curve. IEEE Trans. Biomed. 
Eng. 32, 458–9 (1985). 
48. Bostock, H. The strength-duration relationship for excitation of myelinated nerve: 
computed dependence on membrane parameters. J. Physiol. 341, 59–74 (1983). 
49. Nowak, L. G. & Bullier, J. Axons, but not cell bodies, are activated by electrical 
stimulation in cortical gray matter. Exp. Brain Res. 118, 477–488 (1998). 
50. Mogyoros, I., Kiernan, M. C. & Burke, D. Strength-duration properties of human 
peripheral nerve. Brain 119 ( Pt 2, 439–47 (1996). 
51. Gallistel, C. R. Self-stimulation in the rat: quantitative characteristics of the reward 
pathway. J. Comp. Physiol. Psychol. 92, 977–98 (1978). 
52. Gallistel, C. R. Note on temporal summation in the reward system. J. Comp. 
Physiol. Psychol. 87, 870–5 (1974). 
53. Barry, F. E., Walter, M. S. & Gallistel, C. R. On the optimal pulse duration in 
electrical stimulation of the brain. Physiol. Behav. 12, 749–54 (1974). 
54. Matthews, G. Neural substrate for brain stimulation reward in the rat: cathodal and 
anodal strength-duration properties. J. Comp. Physiol. Psychol. 91, 858–74 (1977). 
55. Koivuniemi, A. S. & Otto, K. J. Asymmetric versus symmetric pulses for cortical 







56. Holsheimer, J., Demeulemeester, H., Nuttin, B. & de Sutter, P. Identification of the 
target neuronal elements in electrical deep brain stimulation. Eur. J. Neurosci. 12, 
4573–7 (2000). 
57. Rizzone, M. et al. Deep brain stimulation of the subthalamic nucleus in 
Parkinson’s disease: effects of variation in stimulation parameters. J. Neurol. 
Neurosurg. Psychiatry 71, 215–9 (2001). 
58. Rattay, F. Analysis of models for extracellular fiber stimulation. IEEE Trans. 
Biomed. Eng. 36, 676–82 (1989). 
59. McIntyre, C. C. & Grill, W. M. Finite Element Analysis of the Current-Density 
and Electric Field Generated by Metal Microelectrodes. Ann. Biomed. Eng. 29, 
227–235 (2001). 
60. McIntyre, C. C., Mori, S., Sherman, D. L., Thakor, N. V & Vitek, J. L. Electric 
field and stimulating influence generated by deep brain stimulation of the 
subthalamic nucleus. Clin. Neurophysiol. 115, 589–95 (2004). 
61. Wei, X. F. & Grill, W. M. Current density distributions, field distributions and 
impedance analysis of segmented deep brain stimulation electrodes. J. Neural Eng. 
2, 139–47 (2005). 
62. Stoney, S. D., Thompson, W. D. & Asanuma, H. Excitation of pyramidal tract 
cells by intracortical microstimulation: effective extent of stimulating current. J. 
Neurophysiol. 31, 659–69 (1968). 
63. Tehovnik, E. J. Electrical stimulation of neural tissue to evoke behavioral 
responses. J. Neurosci. Methods 65, 1–17 (1996). 
64. Goldman, D. E. Potential, impedance, and rectification in membranes. J. Gen. 
Physiol. 27, 37–60 (1943). 
65. McNeal, D. R. Analysis of a model for excitation of myelinated nerve. IEEE Trans. 
Biomed. Eng. 23, 329–37 (1976). 
66. McIntyre, C. C. & Grill, W. M. Excitation of central nervous system neurons by 
nonuniform electric fields. Biophys. J. 76, 878–88 (1999). 
67. Warman, E. N., Grill, W. M. & Durand, D. Modeling the effects of electric fields 
on nerve fibers: determination of excitation thresholds. IEEE Trans. Biomed. Eng. 







68. McIntyre, C. C. & Grill, W. M. Extracellular stimulation of central neurons: 
influence of stimulus waveform and frequency on neuronal output. J. Neurophysiol. 
88, 1592–604 (2002). 
69. McIntyre, C. C., Grill, W. M., Sherman, D. L. & Thakor, N. V. Cellular effects of 
deep brain stimulation: model-based analysis of activation and inhibition. J. 
Neurophysiol. 91, 1457–69 (2004). 
70. Rattay, F. The basic mechanism for the electrical stimulation of the nervous 
system. Neuroscience 89, 335–46 (1999). 
71. Durand, D. M. in The Biomedical Engineering Handbook: Second Edition (ed. 
Bronzino, J. D.) (CRC Press LLC, 2000). doi:10.1201/9781420049510 
72. Rattay, F. Analysis of models for external stimulation of axons. IEEE Trans. 
Biomed. Eng. 33, 974–7 (1986). 
73. BeMent, S. L. & Ranck, J. B. A model for electrical stimulation of central 
myelinated fibers with monopolar electrodes. Exp. Neurol. 24, 171–86 (1969). 
74. Armstrong, D. M., Harvey, R. J. & Schild, R. F. The spatial organisation of 
climbing fibre branching in the cat cerebellum. Exp. Brain Res. 18, 40–58 (1973). 
75. Ranck, J. B. Which elements are excited in electrical stimulation of mammalian 
central nervous system: a review. Brain Res. 98, 417–40 (1975). 
76. Benabid, A. L. et al. Chronic electrical stimulation of the ventralis intermedius 
nucleus of the thalamus as a treatment of movement disorders. J. Neurosurg. 84, 
203–14 (1996). 
77. Porter, R. Focal stimulation of hypoglossal neurones in the cat. J. Physiol. 169, 
630–40 (1963). 
78. Koivuniemi, A. S., Regele, O. B., Brenner, J. H. & Otto, K. J. Rat behavioral 
model for high-throughput parametric studies of intracortical microstimulation. 
Conf. Proc. IEEE Eng. Med. Biol. Soc. 2011, 7541–4 (2011). 
79. Gorman, A. L. Differential patterns of activation of the pyramidal system elicited 
by surface anodal and cathodal cortical stimulation. J. Neurophysiol. 29, 547–64 
(1966). 
80. Hern, J. E., Landgren, S., Phillips, C. G. & Porter, R. Selective excitation of 
corticofugal neurones by surface-anodal stimulation of the baboon’s motor cortex. 








81. Donaldson, N. D. & Donaldson, P. E. When are actively balanced biphasic (’Lilly') 
stimulating pulses necessary in a neurological prosthesis? I. Historical background; 
Pt resting potential; Q studies. Med. Biol. Eng. Comput. 24, 41–9 (1986). 
82. Donaldson, N. D. & Donaldson, P. E. When are actively balanced biphasic (’Lilly') 
stimulating pulses necessary in a neurological prosthesis? II. pH changes; noxious 
products; electrode corrosion; discussion. Med. Biol. Eng. Comput. 24, 50–6 
(1986). 
83. Brummer, S. B. & Turner, M. J. Electrical stimulation of the nervous system: The 
principle of safe charge injection with noble metal electrodes. Bioelectrochemistry 
Bioenerg. 2, 13–25 (1975). 
84. Mortimer, J. T., Shealy, C. N. & Wheeler, C. Experimental nondestructive 
electrical stimulation of the brain and spinal cord. J. Neurosurg. 32, 553–9 (1970). 
85. Schmitt, O. H. & Schmitt, F. O. A universal precision stimulator. Science 76, 328–
30 (1932). 
86. Penfield, W. & Boldrey, E. Somatic motor and sensory representation in the 
cerebral cortex of man as studies by electrical stimulation. Brain 60, 389–443 
(1937). 
87. Butson, C. R. & McIntyre, C. C. Tissue and electrode capacitance reduce neural 
activation volumes during deep brain stimulation. Clin. Neurophysiol. 116, 2490–
500 (2005). 
88. Lempka, S. F., Johnson, M. D., Miocinovic, S., Vitek, J. L. & McIntyre, C. C. 
Current-controlled deep brain stimulation reduces in vivo voltage fluctuations 
observed during voltage-controlled stimulation. Clin. Neurophysiol. 121, 2128–33 
(2010). 
89. Mayberg, H. S. et al. Deep brain stimulation for treatment-resistant depression. 
Neuron 45, 651–60 (2005). 
90. Krauss, J. K. Pallidal deep brain stimulation in patients with cervical dystonia and 
severe cervical dyskinesias with cervical myelopathy. J. Neurol. Neurosurg. 
Psychiatry 72, 249–256 (2002). 
91. Greenberg, B. D. et al. Three-year outcomes in deep brain stimulation for highly 
resistant obsessive-compulsive disorder. Neuropsychopharmacology 31, 2384–93 
(2006). 
92. Schuurman, P. R. et al. A comparison of continuous thalamic stimulation and 








93. Cheung, T. & Tagliati, M. Deep brain stimulation: can we do it better? Clin. 
Neurophysiol. 121, 1979–80 (2010). 
94. Agnesi, F., Blaha, C. D., Lin, J. & Lee, K. H. Local glutamate release in the rat 
ventral lateral thalamus evoked by high-frequency stimulation. J. Neural Eng. 7, 
26009 (2010). 
95. Okun, M. S. et al. Subthalamic deep brain stimulation with a constant-current 
device in Parkinson’s disease: an open-label randomised controlled trial. Lancet 
Neurol. 11, 140–9 (2012). 
96. Foutz, T. J. & McIntyre, C. C. Evaluation of novel stimulus waveforms for deep 
brain stimulation. J. Neural Eng. 7, 066008 (2010). 
97. Grill, W. M. & Mortimer, J. T. Stimulus waveforms for selective neural 
stimulation. IEEE Eng. Med. Biol. Mag. 14, 375–385 (1995). 
98. Millar, J. & Barnett, T. G. The zeta pulse: a new stimulus waveform for use in 
electrical stimulation of the nervous system. J. Neurosci. Methods 77, 1–8 (1997). 
99. Sahin, M. & Tie, Y. Non-rectangular waveforms for neural stimulation with 
practical electrodes. J. Neural Eng. 4, 227–33 (2007). 
100. Wilson, B. S. et al. Better speech recognition with cochlear implants. Nature 352, 
236–8 (1991). 
101. Nie, K., Stickney, G. & Zeng, F.-G. Encoding frequency modulation to improve 
cochlear implant performance in noise. IEEE Trans. Biomed. Eng. 52, 64–73 
(2005). 
102. Birdno, M. J. et al. Stimulus features underlying reduced tremor suppression with 
temporally patterned deep brain stimulation. J. Neurophysiol. 107, 364–83 (2012). 
103. Wyckhuys, T. et al. Suppression of hippocampal epileptic seizures in the kainate 
rat by Poisson distributed stimulation. Epilepsia 51, 2297–304 (2010). 
104. Henderson, M. B. et al. Deep brain stimulation of the nucleus accumbens reduces 
alcohol intake in alcohol-preferring rats. Neurosurg. Focus 29, E12 (2010). 
105. Knapp, C. M., Tozier, L., Pak, A., Ciraulo, D. a & Kornetsky, C. Deep brain 
stimulation of the nucleus accumbens reduces ethanol consumption in rats. 









106. Hasin, D. S., Stinson, F. S., Ogburn, E. & Grant, B. F. Prevalence, correlates, 
disability, and comorbidity of DSM-IV alcohol abuse and dependence in the 
United States: results from the National Epidemiologic Survey on Alcohol and 
Related Conditions. Arch. Gen. Psychiatry 64, 830–42 (2007). 
107. WHO. Global status report on alcohol and health. (2011). 
108. Finney, J. W. & Moos, R. H. The long-term course of treated alcoholism: I. 
Mortality, relapse and remission rates and comparisons with community controls. J. 
Stud. Alcohol 52, 44–54 (1991). 
109. Kennedy, B. P., Isaac, N. E. & Graham, J. D. The role of heavy drinking in the risk 
of traffic fatalities. Risk Anal. 16, 565–569 (1996). 
110. John, U. et al. Excess Mortality of Alcohol-Dependent Individuals After 14 Years 
and Mortality Predictors Based on Treatment Participation and Severity of Alcohol 
Dependence. Alcohol. Clin. Exp. Res. 37, 156–163 (2013). 
111. Bouza, C., Angeles, M., Magro, A., Muñoz, A. & Amate, J. M. Efficacy and safety 
of naltrexone and acamprosate in the treatment of alcohol dependence: a 
systematic review. Addiction 99, 811–28 (2004). 
112. Anton, R. F. et al. Naltrexone and cognitive behavioral therapy for the treatment of 
outpatient alcoholics: results of a placebo-controlled trial. Am. J. Psychiatry 156, 
1758–64 (1999). 
113. Anton, R. F. et al. Combined pharmacotherapies and behavioral interventions for 
alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 
295, 2003–17 (2006). 
114. Kuhn, J. et al. Remission of alcohol dependency following deep brain stimulation 
of the nucleus accumbens: valuable therapeutic implications? J. Neurol. Neurosurg. 
Psychiatry 78, 1152–3 (2007). 
115. Heinze, H.-J. et al. Counteracting incentive sensitization in severe alcohol 
dependence using deep brain stimulation of the nucleus accumbens: clinical and 
basic science aspects. Front. Hum. Neurosci. 3, 22 (2009). 
116. Müller, U. J. et al. Successful treatment of chronic resistant alcoholism by deep 
brain stimulation of nucleus accumbens: first experience with three cases. 
Pharmacopsychiatry 42, 288–91 (2009). 
117. Kuhn, J. et al. Observations on unaided smoking cessation after deep brain 








118. Witjas, T. et al. Addiction in Parkinson’s disease: impact of subthalamic nucleus 
deep brain stimulation. Mov. Disord. 20, 1052–5 (2005). 
119. Mantione, M., van de Brink, W., Schuurman, P. R. & Denys, D. Smoking 
cessation and weight loss after chronic deep brain stimulation of the nucleus 
accumbens: therapeutic and research implications: case report. Neurosurgery 66, 
E218; discussion E218 (2010). 
120. Rouaud, T. et al. Reducing the desire for cocaine with subthalamic nucleus deep 
brain stimulation. Proc. Natl. Acad. Sci. U. S. A. 107, 1196–200 (2010). 
121. Liu, H.-Y. et al. Chronic deep brain stimulation in the rat nucleus accumbens and 
its effect on morphine reinforcement. Addict. Biol. 13, 40–6 (2008). 
122. Vassoler, F. M. et al. Deep brain stimulation of the nucleus accumbens shell 
attenuates cocaine priming-induced reinstatement of drug seeking in rats. J. 
Neurosci. 28, 8735–9 (2008). 
123. Taghva, A., Corrigan, J. D. & Rezai, A. R. Obesity and Brain Addiction Circuitry: 
Implications for Deep Brain Stimulation. Neurosurgery 71, 224–238 (2012). 
124. Vorspan, F., Mallet, L., Corvol, J.-C., Pelissolo, A. & Lépine, J.-P. Treating 
addictions with deep brain stimulation is premature but well-controlled clinical 
trials should be performed. Addiction 106, 1535–6; author reply 1537–8 (2011). 
125. Carter, A., Bell, E., Racine, E. & Hall, W. Ethical Issues Raised by Proposals to 
Treat Addiction Using Deep Brain Stimulation. Neuroethics 4, 129–142 (2010). 
126. Carter, A. & Hall, W. Proposals to trial deep brain stimulation to treat addiction 
are premature. Addiction 106, 235–7 (2011). 
127. Hall, W. & Carter, A. Is deep brain stimulation a prospective “cure” for addiction? 
F1000 Med. Rep. 3, 4 (2011). 
128. Bell, R. L., Rodd, Z. A., Lumeng, L., Murphy, J. M. & McBride, W. J. The 
alcohol-preferring P rat and animal models of excessive alcohol drinking. Addict. 
Biol. 11, 270–88 (2006). 
129. Penn, P. E., McBride, W. J., Lumeng, L., Gaff, T. M. & Li, T. K. Neurochemical 
and operant behavioral studies of a strain of alcohol-preferring rats. Pharmacol. 
Biochem. Behav. 8, 475–481 (1978). 
130. Cicero, T. J., Snider, S. R., Perez, V. J. & Swanson, L. W. Physical dependence on 








131. Di Chiara, G. et al. Dopamine and drug addiction: the nucleus accumbens shell 
connection. Neuropharmacology 47 Suppl 1, 227–41 (2004). 
132. Di Chiara, G. Nucleus accumbens shell and core dopamine: differential role in 
behavior and addiction. Behav. Brain Res. 137, 75–114 (2002). 
133. Ward, M. P. Cranial Nerve Modulation for Treatment-Resistant Major Depressive 
Disorder and Temporal Lobe Epilepsy. (Purdue University, 2012). 
134. Wilden, J. A. et al. Reduced ethanol consumption by alcohol-preferring (P) rats 
following pharmacological silencing and deep brain stimulation of the nucleus 
accumbens shell. J. Neurosurg. 120, 997–1005 (2014). 
135. Crown, W. H. et al. The impact of treatment-resistant depression on health care 
utilization and costs. J. Clin. Psychiatry 63, 963–71 (2002). 
136. Sackeim, H. a et al. Vagus nerve stimulation (VNS) for treatment-resistant 
depression: efficacy, side effects, and predictors of outcome. 
Neuropsychopharmacology 25, 713–28 (2001). 
137. DeGiorgio, C. M. et al. Prospective long-term study of vagus nerve stimulation for 
the treatment of refractory seizures. Epilepsia 41, 1195–1200 (2000). 
138. Labar, D. Vagus nerve stimulation for 1 year in 269 patients on unchanged 
antiepileptic drugs. Seizure 13, 392–398 (2004). 
139. Schachter, S. C. Vagus nerve stimulation therapy summary: five years after FDA 
approval. Neurology 59, S15–S20 (2002). 
140. Ben-Menachem, E. Vagus nerve stimulation, side effects, and long-term safety. J. 
Clin. Neurophysiol. 18, 415–8 (2001). 
141. Labiner, D. M. & Ahern, G. L. Vagus nerve stimulation therapy in depression and 
epilepsy: therapeutic parameter settings. Acta Neurol. Scand. 115, 23–33 (2007). 
142. Mei, N., Condamin, M. & Boyer, A. The composition of the vagus nerve of the cat. 
Cell Tissue Res. 209, (1980). 
143. Foley, J. O. & DuBois, F. S. Quantitative studies of the vagus nerve in the cat. I. 
The ratio of sensory to motor fibers. J. Comp. Neurol. 67, 49–67 (1937). 
144. Friede, R. L. & Samorajski, T. Relation between the number of myelin lamellae 
and axon circumference in fibers of vagus and sciatic nerves of mice. J. Comp. 








145. Gasser, H. The classification of nerve fibers. Ohio J. Sci. Ohio J. Sci. 41, 145–159 
(1941). 
146. Erlanger, J. & Gasser, H. The action potential in fibers of slow conduction in 
spinal roots and somatic nerves. Am. J. Physiol. 92, 43–82 (1930). 
147. Hursh, J. Conduction velocity and diameter of nerve fibers. Am. J. Physiol. 127, 
131–139 (1939). 
148. Woodbury, D. M. & Woodbury, J. W. Effects of vagal stimulation on 
experimentally induced seizures in rats. Epilepsia 31 Suppl 2, S7–19 (1990). 
149. Evans, D. H. & Murray, J. G. Histological and functional studies on the fibre 
composition of the vagus nerve of the rabbit. J. Anat. 88, 320–37 (1954). 
150. Grill, W. M. & Mortimer, J. T. Inversion of the current-distance relationship by 
transient depolarization. IEEE Trans. Biomed. Eng. 44, 1–9 (1997). 
151. Szlavik, R. B. & de Bruin, H. The effect of stimulus current pulse width on nerve 
fiber size recruitment patterns. Med. Eng. Phys. 21, 507–515 (1999). 
152. Blair, E. & Erlanger, J. A comparison of the characteristics of axons through their 
individual electrical responses. Am. J. Physiol. 106, 524–564 (1933). 
153. Mogyoros, I. Strength-duration properties of sensory and motor axons in 
amyotrophic lateral sclerosis. Brain 121, 851–859 (1998). 
154. West, D. C. & Wolstencroft, J. H. Strength-duration characteristics of myelinated 
and non-myelinated bulbospinal axons in the cat spinal cord. J. Physiol. 337, 37–
50 (1983). 
155. Tewfik, T. L. Vagus Nerve Anatomy. Medscape (2013). at 
<http://emedicine.medscape.com/article/1875813-overview> 
156. Cohn, A. E. On the differences in the effects of stimulation of the two vagus 
nerves on rate and conduction of the dog’s heart. J. Exp. Med. 16, 732–757 (1912). 
157. Randall, W. C. & Armour, J. A. Regional vagosympathetic control of the heart. 
Am. J. Physiol. 227, 444–52 (1974). 
158. Ardell, J. L. & Randall, W. C. Selective vagal innervation of sinoatrial and 
atrioventricular nodes in canine heart. Am. J. Physiol. 251, H764–73 (1986). 
159. Ramsay, R. E. et al. Vagus Nerve Stimulation for Treatment of Partial Seizures: 2. 








160. Handforth, A. et al. Vagus nerve stimulation therapy for partial-onset seizures: A 
randomized active-control trial. Neurology 51, 48–55 (1998). 
161. Rutecki, P. Anatomical, physiological, and theoretical basis for the antiepileptic 
effect of vagus nerve stimulation. Epilepsia 31 Suppl 2, S1–6 (1990). 
162. Zabara, J. Inhibition of Experimental Seizures in Canines by Repetitive Vagal 
Stimulation. Epilepsia 33, 1005–1012 (1992). 
163. Koo, B., Ham, S. D., Sood, S. & Tarver, B. Human vagus nerve electrophysiology: 
a guide to vagus nerve stimulation parameters. J. Clin. Neurophysiol. 18, 429–33 
(2001). 
164. Krahl, S. E., Senanayake, S. S. & Handforth, a. Destruction of peripheral C-fibers 
does not alter subsequent vagus nerve stimulation-induced seizure suppression in 
rats. Epilepsia 42, 586–9 (2001). 
165. Krahl, S. E. Vagus nerve stimulation for epilepsy: A review of the peripheral 
mechanisms. Surg. Neurol. Int. 3, S47–52 (2012). 
166. Bhadra, N. & Kilgore, K. L. Direct current electrical conduction block of 
peripheral nerve. IEEE Trans. Neural Syst. Rehabil. Eng. 12, 313–24 (2004). 
167. Kilgore, K. L. & Bhadra, N. Nerve conduction block utilising high-frequency 
alternating current. Med. Biol. Eng. Comput. 42, 394–406 (2004). 
168. Tanner, J. A. Reversible blocking of nerve conduction by alternating-current 
excitation. Nature 195, 712–3 (1962). 
169. Branner, A, Stein, R. B. & Normann, R. a. Selective stimulation of cat sciatic 
nerve using an array of varying-length microelectrodes. J. Neurophysiol. 85, 1585–
94 (2001). 
170. Tyler, D. J. & Durand, D. M. Functionally selective peripheral nerve stimulation 
with a flat interface nerve electrode. IEEE Trans. Neural Syst. Rehabil. Eng. 10, 
294–303 (2002). 
171. Accornero, N., Bini, G., Lenzi, G. L. & Manfredi, M. Selective Activation of 
peripheral nerve fibre groups of different diameter by triangular shaped stimulus 
pulses. J. Physiol. 273, 539–60 (1977). 
172. Tosato, M., Yoshida, K., Toft, E. & Struijk, J. J. Quasi-trapezoidal pulses to 
selectively block the activation of intrinsic laryngeal muscles during vagal nerve 








173. Vuckovic, A., Tosato, M. & Struijk, J. J. A comparative study of three techniques 
for diameter selective fiber activation in the vagal nerve: anodal block, 
depolarizing prepulses and slowly rising pulses. J. Neural Eng. 5, 275–86 (2008). 
174. Qing, K. Y., Ward, M. P. & Irazoqui, P. P. Burst-modulated waveforms optimize 
electrical stimuli for charge efficiency and fibre selectivity. IEEE Trans. Neural 
Syst. Rehabil. Eng. (Accepted). (2015). 
175. Ward, M. P., Rajdev, P., Ellison, C. & Irazoqui, P. P. Toward a comparison of 
microelectrodes for acute and chronic recordings. Brain Res. 1282, 183–200 
(2009). 
176. Ben-Menachem, E., Revesz, D., Simon, B. J. & Silberstein, S. Surgically 
implanted and non-invasive vagus nerve stimulation: a review of efficacy, safety 
and tolerability. Eur. J. Neurol. n/a–n/a (2015). doi:10.1111/ene.12629 
177. Ward, M. P. et al. A flexible platform for biofeedback-driven control and 
personalization of electrical nerve stimulation therapy. IEEE Trans. Neural Syst. 
Rehabil. Eng. (In Press). (2015). 
178. Mollet, L. et al. Electrophysiological responses from vagus nerve stimulation in 
rats. Int. J. Neural Syst. 23, 1350027 (2013). 
179. McDermott, H. An advanced multiple channel cochlear implant. IEEE Trans. 
Biomed. Eng. 36, 789–797 (1989). 
180. Tosato, M., Yoshida, K., Toft, E., Nekrasas, V. & Struijk, J. J. Closed-loop control 
of the heart rate by electrical stimulation of the vagus nerve. Med. Biol. Eng. 
Comput. 44, 161–169 (2006). 
181. Gaskell, W. H. The Croonian Lecture: On the Rhythm of the Heart of the Frog, 
and on the Nature of the Action of the Vagus Nerve. Philos. Trans. R. Soc. London 
173, 993–1033 (1882). 
182. Hunt, S. A. et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 
Guidelines for the Diagnosis and Management of Heart Failure in Adults. A 
Report of the American College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines Developed. J. Am. Coll. Cardiol. 
53, e1–e90 (2009). 
183. Schwartz, P. J. et al. Long term vagal stimulation in patients with advanced heart 
failure. First experience in man. Eur. J. Heart Fail. 10, 884–891 (2008). 
184. De Ferrari, G. M. et al. Chronic vagus nerve stimulation: A new and promising 








185. Mortara, A. et al. Arterial baroreflex modulation of heart rate in chronic heart 
failure: clinical and hemodynamic correlates and prognostic implications. 
Circulation 96, 3450–3458 (1997). 
186. Adamson, P. B. et al. Continuous autonomic assessment in patients with 
symptomatic heart failure: Prognostic value of heart rate variability measured by 
an implanted cardiac resynchronization device. Circulation 110, 2389–2394 
(2004). 
187. Thayer, J. F., Yamamoto, S. S. & Brosschot, J. F. The relationship of autonomic 
imbalance, heart rate variability and cardiovascular disease risk factors. Int. J. 
Cardiol. 141, 122–131 (2010). 
188. Sander, J. W. The epidemiology of epilepsy revisited. [Curr Opin Neurol. 2003] - 
PubMed result. Curr. Opin. Neurol. 16, 165–70 (2003). 
189. Shackleton, D. P., Westendorp, R. G. J., Kasteleijn-Nolst Trenité, D. G. a, de 
Craen, A. J. M. & Vandenbroucke, J. P. Survival of patients with epilepsy: an 
estimate of the mortality risk. Epilepsia 43, 445–450 (2002). 
190. Zieliński, J. J. Epilepsy and mortality rate and cause of death. Epilepsia 15, 191–
201 (1974). 
191. Annegers, J. F. & Coan, S. P. SUDEP: Overview of definitions and review of 
incidence data. Seizure 8, 347–352 (1999). 
192. Walczak, T. S. et al. Incidence and risk factors in sudden unexpected death in 
epilepsy: a prospective cohort study. Neurology 56, 519–525 (2001). 
193. Tomson, T., Nashef, L. & Ryvlin, P. Sudden unexpected death in epilepsy: current 
knowledge and future directions. Lancet Neurol. 7, 1021–1031 (2008). 
194. Leestma, J. E., Walczak, T., Hughes, J. R., Kalelkar, M. B. & Teas, S. S. A 
prospective study on sudden unexpected death in epilepsy. Ann. Neurol. 26, 195–
203 (1989). 
195. P-Codrea, S., Dalager-pedersen, S., Dam, M. & Vesterby-charles, A. Sudden 
Unexpected Death in Epilepsy. Am. J. Forensic Med. Pathol. 26, 99–105 (2005). 
196. Falconer, B. & Rajs, J. Post-mortem findings of cardiac lesions in epileptics: a 
preliminary report. Forensic Sci. 8, 63–71 (1976). 
197. Natelson, B. H., Suarez, R. V, Terrence, C. F. & Turizo, R. Patients with epilepsy 








198. Annegers, J. F., Hauser, W. A. & Shirts, S. B. Heart disease mortality and 
morbidity in patients with epilepsy. Epilepsia 25, 699–704 (1984). 
199. Nei, M., Ho, R. T. & Sperling, M. R. EKG abnormalities during partial seizures in 
refractory epilepsy. Epilepsia 41, 542–548 (2000). 
200. Zijlmans, M., Flanagan, D. & Gotman, J. Heart rate changes and ECG 
abnormalities during epileptic seizures: Prevalence and definition of an objective 
clinical sign. Epilepsia 43, 847–854 (2002). 
201. Sevcencu, C. & Struijk, J. J. Autonomic alterations and cardiac changes in 
epilepsy. Epilepsia 51, 725–737 (2010). 
202. Nashef, L. et al. Apnoea and bradycardia during epileptic seizures: relation to 
sudden death in epilepsy. J. Neurol. Neurosurg. Psychiatry 60, 297–300 (1996). 
203. Eggleston, K. S., Olin, B. D. & Fisher, R. S. Ictal tachycardia: The head-heart 
connection. Seizure 23, 496–505 (2014). 
204. Drake, M. E., Reider, C. R. & Kay, a. Electrocardiography in epilepsy patients 
without cardiac symptoms. Seizure 2, 63–65 (1993). 
205. Lotufo, P. A., Valiengo, L., Benseñor, I. M. & Brunoni, A. R. A systematic review 
and meta-analysis of heart rate variability in epilepsy and antiepileptic drugs. 
Epilepsia 53, 272–282 (2012). 
206. Stöllberger, C. & Finsterer, J. Cardiorespiratory findings in sudden 
unexplained/unexpected death in epilepsy (SUDEP). Epilepsy Res. 59, 51–60 
(2004). 
207. Schomer, A. C., Nearing, B. D., Schachter, S. C. & Verrier, R. L. Vagus nerve 
stimulation reduces cardiac electrical instability assessed by quantitative T-wave 
alternans analysis in patients with drug-resistant focal epilepsy. Epilepsia 55, 
1996–2002 (2014). 
208. Zannad, F. et al. Chronic vagal stimulation for the treatment of low ejection 
fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure 
(NECTAR-HF) randomized controlled trial. Eur. Heart J. 36, 425–433 (2015). 
209. Hauptman, P. J. et al. Rationale and study design of the INcrease of Vagal TonE in 
Heart Failure study: INOVATE-HF. Am. Heart J. 163, 954–962.e1 (2012). 
210. Grill, W. M., Snyder, C. A. A. N. & Miocinovic, S. Deep brain stimulation creates 








211. Warner, H. R. & Cox, a. A mathematical model of heart rate control by 
sympathetic and vagus efferent information. J. Appl. Physiol. 17, 349–355 (1962). 
212. Warner, H. R. & Russell, R. O. Effect of combined sympathetic and vagal 
stimulation on heart rate in the dog. Circ. Res. 24, 567–573 (1969). 
213. Navas, M. et al. Treatment of refractory epilepsy in adult patients with right-sided 
vagus nerve stimulation. Epilepsy Res. 90, 1–7 (2010). 
214. Pfeffer, J., Pfeffer, M., Fletcher, P. & Braunwald, E. Alterations of cardiac 
performance in rats with established spontaneous hypertension. Am. J. Cardiol. 44, 
994–998 (1979). 
215. Fletcher, P. J., Pfeffer, J. M., Pfeffer, M. A. & Braunwald, E. Left ventricular 
diastolic pressure-volume relations in rats with healed myocardial infarction. 
Effects on systolic function. Circ. Res. 49, 618–626 (1981). 
216. DeGeest, H., Levy, M. N., Zieske, H. & Lipman, R. I. Depression of ventricular 
contractility by stimulation of the vagus nerves. Circ. Res. 17, 222–235 (1965). 
217. Matsuura, W. et al. Vagal stimulation decreases left ventricular contractility 
mainly through negative chronotropic effect. Am. J. Physiol. 273, H534–H539 
(1997). 
218. Koller, W. C., Lyons, K. E., Wilkinson, S. B., Troster, a I. & Pahwa, R. Long-term 
safety and efficacy of unilateral deep brain stimulation of the thalamus in essential 
tremor. Mov. Disord. 16, 464–8 (2001). 
219. Burchiel, K. J., Anderson, V. C., Favre, J. & Hammerstad, J. P. Comparison of 
pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson’s 
disease: results of a randomized, blinded pilot study. Neurosurgery 45, 1375–82; 
discussion 1382–4 (1999). 
220. Rodriguez-Oroz, M. C. et al. Bilateral deep brain stimulation in Parkinson’s 
disease: a multicentre study with 4 years follow-up. Brain 128, 2240–9 (2005). 
221. Kleiner-Fisman, G. et al. Subthalamic nucleus deep brain stimulation: summary 
and meta-analysis of outcomes. Mov. Disord. 21 Suppl 1, S290–304 (2006). 
222. Tamma, F. et al. Anatomo-clinical correlation of intraoperative stimulation-
induced side-effects during HF-DBS of the subthalamic nucleus. Neurol. Sci. 23 
Suppl 2, S109–10 (2002). 
223. Kent, A. R. & Grill, W. M. Instrumentation to record evoked potentials for closed-








Conference of the IEEE Engineering in Medicine and Biology Society, EMBS 
6777–6780 (2011). doi:10.1109/IEMBS.2011.6091671 
224. McCracken, C. B. & Grace, A. a. Nucleus accumbens deep brain stimulation 
produces region-specific alterations in local field potential oscillations and evoked 
responses in vivo. J. Neurosci. 29, 5354–5363 (2009). 
225. Behrend, C. E. et al. Toward feedback controlled deep brain stimulation: 
Dynamics of glutamate release in the subthalamic nucleus in rats. J. Neurosci. 
Methods 180, 278–289 (2009). 
226. Luigjes, J. et al. Deep brain stimulation in addiction: a review of potential brain 
targets. Mol. Psychiatry 17, 572–83 (2012). 
227. Vassoler, F. M. et al. Deep brain stimulation of the nucleus accumbens shell 
attenuates cocaine reinstatement through local and antidromic activation. J. 
Neurosci. 33, 14446–54 (2013). 
228. Wise, R. A. Drug-activation of brain reward pathways. Drug Alcohol Depend. 51, 
13–22 (1998). 
229. Irazoqui, P. P., Ward, M. P. & Qing, K. Y. Burst pulse tissue stimulation method 
and apparatus. (2014). 
230. Mellanby, J., George, G., Robinson, a & Thompson, P. Epileptiform syndrome in 
rats produced by injecting tetanus toxin into the hippocampus. J. Neurol. 
Neurosurg. Psychiatry 40, 404–14 (1977). 
231. Jefferys, J. G. & Williams, S. F. Physiological and behavioural consequences of 
seizures induced in the rat by intrahippocampal tetanus toxin. Brain 110 ( Pt 2, 























KURT Y. QING 
 
EDUCATION 
Purdue University, West Lafayette, IN August 2011 – May 2015 
Doctor of Philosophy in Engineering (projected) 
Biomedical Engineering 
 
Indiana University School of Medicine, Indianapolis, IN 
 August 2009 – May 2017 
Doctor of Medicine (combined with PhD) (projected) 
 
Northwestern University, Evanston, IL August 2005 – December 2008 
Bachelors in Science 
Biomedical Engineering 
Minor in Global Health 
 
AWARDS 
Dean’s Council Scholarship, Indiana University School of Medicine 2009 – 2011 
 
Creativity Foundation Legacy Prize  2010 
(http://creativity-found.org/legacy-prize/entry/kurt-y-qing/) 
 
CIMIT Prize finalist, CIMIT  2009 
(http://www.cimit.org/news/cimit-prize-09-winners.html) 
 
Advanced E-Team Funded Project, NCIIA (now VentureWell) 2008 – 2009 
(http://nciia.org/sites/default/files/newsletter_spring_2009.pdf) 
 













Biomedical Engineering, Purdue University 
Advisor: Pedro Irazoqui 
Graduate research assistant August 2011 – May 2015 
- Fabrication and characterization of nerve and brain microelectrodes 
- Design, fabrication, and characterization of printed circuit boards for 
stimulation and recording in animals 
- Design and testing of application-specific integrated circuits 
- Developing and conducting animal surgery and experimentation 
- Developing and studying rat model of chronic epilepsy 
- Biomedical instrumentation 
- Custom graphical user interphase and complex routines in MATLAB 
- Closed-loop neurostimulation, deep brain stimulation, vagus nerve stimulation 
- Statistical analysis 
 
KMC ApneAlert, Northwestern University 
Advisor: Matthew Glucksberg 
Design team leader January 2008 – August 2009 
- Led circuitry design and modification.  
- Led device prototyping and bench top testing.  
- Obtained IRB approval and led device testing on human subjects at Prentice 
Women’s Hospital in Chicago and Karl Bremer Hospital in Western Cape, 
South Africa.  
- Wrote grants and secured funding for the project.  
- Coordinated research and design efforts with nurses, doctors, and a device 
manufacturer in South Africa. 
 
Biomedical Engineering, Northwestern University 
Advisor: Robert Linsenmeier 
Independent student researcher September 2007 – August 2009 
- Designed and experimented with a real-time recording system for measuring 
the pH of cultured human tissue for Children's Memorial Research Center 
 
Biomedical Engineering, Northwestern University 
Advisor: Robert Linsenmeier 
Undergraduate research assistant June 2007 – August 2007 
- Supported real-time, in vivo oxygen measurements in rat retina by fabricating 
recording electrodes and assisting surgical preparations.  















Qing, K. Y., Ward, M. P. & Irazoqui, P. P. Controlling the vagal effects on the heart by 
B fiber activation (tentative title). (In Preparation). (2015). 
 
Qing, K. Y., Ward, M. P. & Irazoqui, P. P. Burst-modulated waveforms optimize 
electrical stimuli for charge efficiency and fibre selectivity. IEEE Trans. Neural 
Syst. Rehabil. Eng. (Accepted). (2015). 
 
Wilden, J. A., Qing, K. Y., et. al. Reduced ethanol consumption by alcohol-preferring (P) 
rats following pharmacological silencing and deep brain stimulation of the nucleus 
accumbens shell. J. Neurosurg. 120, 997–1005 (2014). 
 
Ward, M. P., Qing, K. Y., et al. A flexible platform for biofeedback-driven control and 
personalization of electrical nerve stimulation therapy. IEEE Trans. Neural Syst. 
Rehabil. Eng. (In Press). (2015). 
 
Dryg, I. D., Ward, M. P., Qing, K. Y., et al. Magnetically inserted neural electrodes: 






Irazoqui, P. P., Ward, M. P. & Qing, K. Y. Burst pulse tissue stimulation method and 
apparatus. (2014, provisional).* 
 
* Qing, K. Y. should be first inventor. A full patent is currently being prepared. 
